



EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
22.04.2015 Bulletin 2015/17

(21) Application number: **06719512.3**

(22) Date of filing: **25.01.2006**

(51) Int Cl.:
G01N 33/53 (2006.01) G01N 33/573 (2006.01)

(86) International application number:
PCT/US2006/002678

(87) International publication number:
WO 2006/081308 (03.08.2006 Gazette 2006/31)

(54) **PLASMODIUM DIAGNOSTIC ASSAY**

PLASMODIUM-DIAGNOSETEST

ANALYSE DIAGNOSTIQUE DE PLASMODIUM

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR**

(30) Priority: **25.01.2005 US 646893 P**

(43) Date of publication of application:
14.11.2007 Bulletin 2007/46

(73) Proprietor: **The Johns Hopkins University
Baltimore, MD 21218 (US)**

(72) Inventors:
• **SULLIVAN, David, J.**
Baltimore, MD 21210 (US)
• **SCHOLL, Peter**
Baltimore, MD 21212 (US)

(74) Representative: **Adam, Holger**
Kraus & Weisert
Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München (DE)

(56) References cited:
WO-A-02/092628 WO-A-2004/053086
FR-A- 2 791 685 US-A1- 2002 127 241

- **DATABASE NCBI PROTEINS [Online] NCBI; 2
December 2004 (2004-12-02), "hypothetical
protein [Plasmodium falciparum 3D7]"
XP002508841 retrieved from NCBI Database
accession no. CAD52368**

- **PINTO M.J.W. ET AL.: 'Rapid diagnosis of
falciparum malaria by detection of Plasmodium
falciparum HRP-2 antigen'
J.ASSOC.PHYSICIANS INDIA vol. 47, no. 11, 1999,
pages 1076 - 1078, XP008075757**
- **IQBAL J. ET AL.: 'Diagnosis of imported malaria
by Plasmodium lactate dehydrogenase (pLDH)
and histidine-rich protein 2 (PfHRP-2)-based
immunocapture assays' AM. J. TROP. HYG. vol.
64, no. 1,2, 2001, pages 20 - 23, XP003007426**
- **ARDESHIR F. ET AL.: 'Cross-reactive
asparagine-rich determinants shared between
several blood-stage antigens of Plasmodium
falciparum and the circumsporozoite protein'
MOL. BIOCHEM. PARASITOL. vol. 40, 1990,
pages 113 - 128, XP003007427**
- **DESAKORN V. ET AL.: 'Semi-quantitative
measurement of Plasmodium falciparum antigen
PfHRP2 in blood and plasma' TRANS. R. SOC.
TROP. MED. HYG. vol. 91, no. 4, 1997, pages 479
- 483, XP003007428**
- **PALMER C.J. ET AL.: 'Evaluation of the OptiMAL
test for rapid diagnosis of Plasmodium vivax and
Plasmodium falciparum' J. CLIN. MICROBIOL.
vol. 36, no. 1, January 1998, pages 203 - 206,
XP000923205**
- **RICHTER J. ET AL.: 'Co-reactivity of plasmodium
histidine-rich protein 2 and aldolase on a
combined immuno-chromographic malaria
dipstick (ICT) as a potential semi-quantitative
marker of high Plasmodium falciparum
parasitemia' PARASITOL. RES. vol. 94, 2004,
pages 384 - 385, XP003007429**
- **MOODY A.: 'Rapid diagnostic tests for malaria
parasites' CLIN. MICROBIOL. REV. vol. 15, no. 1,
January 2002, pages 66 - 78, XP003007430**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- | | |
|---|--|
| <ul style="list-style-type: none">• STAHL H.D. ET AL.: 'An asparagine-rich protein from blood stages of Plasmodium falciparum shares determinants with sporozoites' NUCLEIC ACID RES. vol. 14, no. 7, 1986, pages 3089 - 3102, XP008075760• D.N.A. Militao ET AL: "Detection of Antigens in the Urine of Patients with Acute Plasmodium vivax Malaria", Experimental Parasitology, vol. 76, no. 2, 1 March 1993 (1993-03-01), pages 115-120, XP055041898, ISSN: 0014-4894, DOI: 10.1006/expr.1993.1013 | <ul style="list-style-type: none">• B GENTON ET AL: 'DiagnosisDiagnosis of Plasmodium falciparum infection using ParaSight(R)-F test in blood and urine of Papua New Guinean children.' SOUTHEAST ASIAN J TROP MED PUBLIC HEALTH vol. 29, March 1998, pages 35 - 40, XP009164007 |
|---|--|

Description

BACKGROUND OF THE INVENTION

[0001] Malaria kills over 2.7 million people annually amongst the 300-500 million clinical cases worldwide. Malaria is increasingly imported into countries where it is non-endemic and there is an increase in the emergence of drug resistant strains. Malaria predominantly occurs in resource-poor tropical populations where diagnostic capabilities are inadequate. The gold standard blood film malaria diagnostic assay relies on phlebotomy and technical expertise. However, in impoverished populations, the lack of resources to safely draw blood increases the risk of transmitting diseases such as hepatitis B and HIV. Thus, simple assays are much needed in the art to improve the availability of malaria diagnosis to obviate the occupational hazards involved in phlebotomy, to provide better treatment options to those in need, and to differentiate between symptomatic and asymptomatic disease.

[0002] It is an object of this invention to provide a rapid, sensitive method for detecting *Plasmodium* analytes in body fluids. Another object is to provide an assay that has high sensitivity.

[0003] WO 2004/053086 discloses *Plasmodium falciparum* antigens useful in therapeutic and diagnostic applications. Specifically presented is a summary of immune reactivities of a panel of 27 novel antigens and four known antigens.

[0004] FRA 2 791 685 discloses a polypeptide produced by *Plasmodium falciparum* having serine protease activity. Said polypeptide is used for a vaccination against an infection with *Plasmodium falciparum*.

[0005] WO 02/092628 discloses *Plasmodium falciparum* antigens and vaccine and diagnostic applications thereof.

[0006] US 2002/127241 discloses compositions that inhibit the binding of the *Plasmodium falciparum* erythrocytes which include a family of erythrocyte binding proteins. Said compositions are used for detecting, diagnosing, preventing and treating *Plasmodium falciparum* and *Plasmodium falciparum*-related infections.

SUMMARY

[0007] This invention relates to assays for analytes in a liquid sample selected from nasal fluid, urine, sweat, tears, pus, saliva or sputum. More particularly, the invention relates to a method and apparatus for the detection of a *Plasmodium* ligand in said fluids.

[0008] In one aspect, the invention relates to a method of diagnosing a *Plasmodium* infection in a subject, comprising detecting the presence or absence of one or more poly asparagine proteins being expressed by a *Plasmodium* species and comprising 12 or more consecutive asparagine amino acid residues in a sample taken from a subject selected from nasal fluid, urine, sweat, tears, pus, saliva or sputum, wherein the presence of one or more poly asparagine proteins is indicative of a *Plasmodium* infection.

[0009] Examples of the poly asparagine proteins are listed in Table 1.

[0010] In one aspect, methods of diagnosing a *Plasmodium* infection in a subject, comprise further detecting the presence or absence of HRP II, HRP III and aldolase or fragments thereof in a biological sample of subject.

[0011] In one embodiment, if the sample is urine, buffering the sample to a pH of between about 4 to about 9.

[0012] In a further embodiment, if the sample is urine, buffering the sample to a pH of about 7.5 to about 8.5.

[0013] In one embodiment, the methods may further comprise detecting the presence or absence of one or more additional *Plasmodium* proteins or fragments thereof.

[0014] In one embodiment, the one or more additional proteins comprise histidine rich protein II (HRP II, HRP III), aldolase, lactate dehydrogenase, one or more poly-asparagine proteins or fragments or variants thereof.

[0015] In yet another embodiment, the *Plasmodium* is one or more of *Plasmodium falciparum*, *Plasmodium yoelii*, *Plasmodium knowlesi*, *Plasmodium brasilaneum*, *Plasmodium ovale*, *Plasmodium chabaudi*, *Plasmodium vivax*, *Plasmodium malariae*, *Plasmodium berghei*, *Plasmodium reichenowi*, *Plasmodium gallinaceum*.

[0016] In one aspect, methods of differentially diagnosing symptomatic *Plasmodium* infection from asymptomatic *Plasmodium* infection and no infection, comprise a method of differentially diagnosing symptomatic *Plasmodium* infection from asymptomatic *Plasmodium* infection and no infection, comprising: detecting the level of one or more poly asparagine proteins in a sample taken from a subject, selected from nasal fluid, urine, sweat, tears, pus, saliva or sputum, with a lateral flow device, wherein the poly asparagine proteins are expressed by a *Plasmodium* species and comprise 12 or more consecutive asparagine amino acid residues, and correlating a low level or lack of detection poly asparagine proteins with asymptomatic disease or no infection.

[0017] In one embodiment, the detecting is with a lateral flow device, mass spectrometry, immunoassay, or colorimetric assay.

[0018] In yet another embodiment, the immunoassay selected from one or more of ELISA, immunoprecipitation, immunodiffusion, radioimmunoassay, immunofluorescence, or lateral flow assay.

[0019] In one aspect, methods of detecting the presence of a *Plasmodium* analyte in a sample, comprise a method of detecting the presence of a *Plasmodium* analyte in a sample, comprising: applying a sample, selected from nasal

fluid, urine, sweat, tears, pus, saliva or sputum, to an assay device, wherein the assay device comprises a sample receiving membrane which conducts flow of a liquid sample in flow contact with an analyte detection membrane which conducts flow of the sample, wherein the analyte detection membrane comprises a conjugate forming membrane comprising a mobile labeling reagent at a labeling situs, and an immobile capture reagent at a capture situs, wherein the labeling reagent is capable of forming a complex with a poly-asparagine protein and the capture reagent is capable of binding a poly-asparagine protein-labeling reagent complex, wherein the poly asparagine proteins are expressed by a *Plasmodium* species and comprise 12 or more consecutive asparagine amino acid residues, wherein said liquid sample flows from the sample receiving membrane and mixes with the mobile labeling reagent to move the mobile labeling reagent toward the control situs, and observing a result of the assay.

[0020] In one embodiment, the poly asparagine protein is one or more of the proteins listed in Table 1.

[0021] In one embodiment, the flow is lateral flow.

[0022] In a further embodiment, the assay device further comprises a second mobile labeling reagent at the labeling situs, and a second immobile capture reagent at the capture situs, wherein the second mobile labeling reagent is capable of forming a complex with HRP II, HRP III or a fragment or variant thereof and the capture reagent is capable of binding HRP II, HRP III -labeling reagent complex.

[0023] In one embodiment, the methods may further comprise a second mobile labeling reagent at the labeling situs, and a second immobile capture reagent at the capture situs, wherein the second mobile labeling reagent is capable of forming a complex with aldolase or a fragment or variant thereof and the capture reagent is capable of binding aldolase-labeling reagent complex.

[0024] In yet another embodiment, the assay device further comprises a second mobile labeling reagent at the labeling situs, and a second immobile capture reagent at the capture situs, wherein the second mobile labeling reagent is capable of forming a complex with lactate dehydrogenase or a fragment or variant thereof and the capture reagent is capable of binding lactate dehydrogenase-labeling reagent complex.

[0025] In one aspect, methods of detecting the presence of a *Plasmodium* analyte in a sample, comprise a method of detecting the presence of a *Plasmodium* analyte in a sample, selected from nasal fluid, urine, sweat, tears, pus, saliva or sputum, comprising: applying the sample to an assay device, wherein the assay device comprises a sample receiving membrane which conducts flow of a liquid sample in flow contact with an analyte detection membrane which conducts flow of the sample, wherein the analyte detection membrane comprises a conjugate forming membrane comprising a first and a second mobile labeling reagent at a labeling situs, and a first and a second immobile capture reagent at a capture situs, wherein the first labeling reagent is capable of forming a complex with a HRP II, HRP III or a fragment or variant thereof; the second labeling reagent is capable of forming a complex with a poly asparagine protein, the first capture reagent is capable of binding a HRP II, HRP III-labeling reagent complex; and the second capture reagent is capable of binding a poly asparagine protein, aldolase, or lactate dehydrogenase-labeling reagent complex, and wherein said liquid sample flows from the sample receiving membrane and mixes with the mobile labeling reagent to move the mobile labeling reagent toward the control situs, and observing a result of the assay, wherein the poly asparagine proteins are expressed by a *Plasmodium* species and comprise 12 or more consecutive asparagine amino acid residues.

[0026] In a further embodiment, the poly asparagine protein is one or more of the proteins listed in Table 1.

[0027] In one embodiment, an accumulation of particles at the capture situs produces an indicative signal of the presence of the *Plasmodium* analyte in the sample.

[0028] Further described is an assay device for detection of the presence or absence of a *Plasmodium* analyte in a sample as defined above which comprises (a) a sample receiving membrane which conducts flow of a sample, and in flow contact with, and (b) an analyte detection membrane which conducts flow of the sample comprising a conjugate forming membrane comprising a first and a second mobile labeling reagent at a labeling situs and a first and a second immobile capture reagent at a capture situs, wherein the labeling reagents are capable of forming complexes with a poly-asparagine protein-labeling reagent complex, wherein the polyasparagine proteins comprise 12 or more consecutive asparagine amino acid residues.

[0029] In yet another embodiment, the poly asparagine protein is one or more of the proteins listed in Table 1.

[0030] In one embodiment, the flow contact between the sample receiving membrane and analyte detection membrane is lateral flow contact.

[0031] In a further embodiment, the back of the sample receiving membrane and the analyte detection membrane are laminated with a semi-rigid material.

[0032] In one embodiment, the sample receiving membrane and the analyte detection membrane are enclosed in a housing.

[0033] In one embodiment, the housing comprises a sample application aperture and an observation window positioned to display the immobile capture situs and control situs.

[0034] In one embodiment, the devices may further comprise an absorbent sink in lateral flow contact with the analyte detection membrane.

[0035] In one embodiment, the devices may further comprise a control reagent immobilized at a control situs.

[0036] In a further embodiment, the control reagent comprises an anti-mouse IgG, an anti-goat IgG, an anti-cow IgG, anti-rabbit IgG, or an anti-rat IgG.

[0037] In one embodiment, the control reagent is immobilized between the immobile capture reagent and an end of the analyte detection membrane.

[0038] Further described are kits comprising an assay device comprising (a) a sample receiving membrane which conducts flow of a sample, and in flow contact with, (b) an analyte detection membrane which conducts flow of the sample comprising a conjugate forming membrane comprising mobile labeling reagent at a labeling situs and a immobile capture reagent at a capture situs, wherein the labeling reagent is capable of forming complexes a poly-asparagine proteins, and the capture reagent is capable of binding a poly-asparagine protein, -labeling reagent complex; and instructions for use, wherein the poly asparagine proteins are expressed by a *Plasmodium* species and comprise 12 or more consecutive asparagine amino acid residues.

[0039] Preferably, the back of the sample receiving membrane and the analyte detection membrane are laminated with a semi-rigid material. The semi-rigid material may be at least 0.005 inches thick to produce a device with adequate mechanical strength in the absence of a plastic casing. In a related embodiment, the sample receiving membrane and the analyte detection membrane are enclosed in a housing. The housing, may have a sample application aperture and an observation window positioned to display the immobile capture situs and control situs.

[0040] In a further embodiment, the device further comprises an absorbent sink in lateral flow contact with the analyte detection membrane.

[0041] In yet another embodiment, the device further comprises a control reagent immobilized at a control situs.

[0042] Another aspect of the invention is a kit comprising an assay device as described above and instructions for use.

[0043] Other embodiments of the invention are disclosed *infra*.

BRIEF DESCRIPTION OF THE DRAWINGS

[0044]

Figure 1 depicts the immunochromatographic analysis using a blood based test of 12 urine samples from individuals infected with *P. falciparum*. The urine was buffered to pH 8 before analysis of 15 microliters. Urine positive for *P. falciparum* histidine-rich protein (HRP) II in 10 of 12 samples and positive for aldolase in 5 of 12 samples. Urine positive for blood-Mal urine 1 only; Urine ketones positive-sample Mal urine 1, 2, 4, 8, 9, 10, 11. Protein is 1-2+ for all samples except mal urine 7, which was more dilute. Positive controls were *P. falciparum* culture and recombinant HRP II and III and a malaria nonendemic negative control. HRP II and aldolase can be detected in urine.

Figure 2 shows lack of detection of intact lactate dehydrogenase by a blood based immunochromatographic test in the urine. 15 microliters of urine was mixed with reagents. No Pf LDH is detected in the nine urine samples corresponding to Mal urine 1-9 in figure 1 by this analysis. Without wishing to be bound by any scientific theory, this particular antibody may detect native noncleaved antigen only.

Figure 3 depicts monoclonal HRP II and III antibody that detects both HRP II and III (clone 3A4) and another that is more specific to HRP II (clone 4A5). A. ELISA to HRP II and HRP III. B. Western blot probed with 3A4 to cultured parasites clones 3D7 and HB3. C. recombinant HRP II and III as marked with arrows and the repetitive motif in lower left two lanes as in legend probed with antibody 3A4 (SEQ ID NOs:8 & 9 are disclosed respectively in order of appearance.) D. Additional parasite clones with HRP II in top and HRP III only in bottom.

Figure 4 depicts that monoclonal anti-HRP II and III antibodies detect HRP II and III from worldwide divergent isolates. HB3 has only HRP II, Dd2 and D10 have only HRP III and 3D7 and 7G8 have both HRP II and III. This suggests 3A4 antibody has a higher affinity for both HRP II and III while 4A5 does not detect HRP III as well.

Figure 5 depicts an anti-HRP II and III antibodies which are specific for HRP II on recombinant HB3-HRP II and recombinant D10 HRP III by ELISA.

Figure 6 depicts detection of recombinant HB3 HRP II in blood and serum. Lower limit of detection is approximately a nanogram of HRP II. A million parasites contain approximately 1.3 ng of PfHRP II. The approximate lower level of detection is 10,000 parasites per microliter (~0.1% parasitemia) for a direct dilution of 10 μ l in 100 μ l of assay.

Figure 7 depicts the probing of two aldolase monoclonal antibodies, 2E12 and 6B10, to *Plasmodium* aldolase from different *Plasmodium* species. Lanes; 1 Pvivax (D19), 2 *P. falciparum* (3D7), 3 *P. yoelii*, 4 *P. knowlesi*, 5. *P. brasi-*

laneum, 6. *P. ovale*, 7. *P. vivax* (D73), 8. *P. chabaudi*. Lanes 6 and 8 from mouse species also show secondary antibody reactive to heavy and light chains.

Figure 8 shows representative sequence of HRP II and III. The number of repeat units varies but common 6 amino acid residues such as AHHAHHAA (SEQ ID NO: 3) or AHHAAD (SEQ ID NO: 4) are in both HRP II or III. The epitope seen by different HRP II/III antibodies will vary. For instance AHHAHHAA (SEQ ID NO: 5) or AHHAAD (SEQ ID NO: 6) appears infrequently with HRP III.

Figure 9 depicts Western blot twelve urine samples from individuals infected with *P. falciparum*. Western blot with new monoclonal 3A4 detects pfHRP II in 70% of urines that were not concentrated. Eight out of twelve were positive from 30 μ L of urine. Blood in urine-sample 1 - only Protein is 1-2+ for all samples.

Figure 10 depicts novel malaria urine dipstick test results for limit of detection. The malaria urine test was able to detect 40 pcg of HRP II in 200 μ L of urine. This is about 25-30 times more sensitive than most ICT blood tests, Western Blot or ELISA.

Figure 11 depicts novel malaria urine dipstick test results on archival frozen samples that were used Figure 1. Seven of none were positive for HRP II and samples 8 and 11 were still negative.

Figure 12 depicts test results of novel malaria urine dipstick from first positive field sample.

Figure 13 depicts test results of novel malaria urine dipstick for 12 field patient samples demonstrating that HRP II band is positive in symptomatic patients but negative in asymptomatic patients.

Figure 14A and B depict schematics of a device according to the invention.

Figure 15 depicts a top view of a device according to the invention.

Figure 16 depicts a top schematic view of a device according to the invention.

Figure 17A depicts a top view and 17B depicts side view of a device according to the invention.

Figure 18 depicts a top view of a device according to the invention.

DETAILED DESCRIPTION OF THE INVENTION

[0045] Described herein are assay devices to determine the presence or absence of a *Plasmodium* analyte in a sample. Further disclosed herein are methods for determining the presence or absence of a *Plasmodium* analyte in a sample as defined above. The devices and methods of this invention provide safe and accurate diagnostic tests for malaria.

[0046] Broadly, the devices and methods of the invention can be used to detect *Plasmodium* analytes that may be assayed using known immunoassay procedures, or known to be detectable by such procedures, using antibodies or other proteins comprising binding sites for analytes. Various specific assay protocols, reagents, and analytes useful in the practice of the invention are found, for example, in U.S. Pat. No. 4,313,734, and U.S. Pat. No. 4,366,241.

[0047] As used herein, the term, "analyte" is intended to refer to any component of a sample (e.g., molecule, compound, or aggregate thereof) to be detected and optionally quantitatively determined by an assay device. Examples of analytes include proteins, (e.g., proteins expressed by or caused to be expressed by *Plasmodium* infection, e.g., HRP II and III, aldolase, poly-asparagine proteins, lactate dehydrogenase, and fragments and variants thereof. Sandwich assays, for example, may be performed for analytes such as HRP II and III, aldolase, anti-asparagine proteins, lactate dehydrogenase and fragments and variants thereof. Competition assays, for example, may be carried out for analytes such as HRP II and III, aldolase, proteins with poly-asparagines, lactate dehydrogenase fragments and variants thereof.

[0048] It may be desired to assay two or more different analytes using the same device. In such instances, it may be desirable to employ different detectable markers on the same test strip where each detectable marker detects a different analyte. For example, different detectable markers may be attached to different mobile labeling reagents. The different detectable markers may be different fluorescent agents, which fluoresce at different wavelengths or differently colored dyes or particles. When detecting two or more different analytes using the same device, separate test detection or capture zones may optionally be formed on the test strip for each analyte to be detected. The same detectable marker may be used for all of the analytes. Alternatively, different detectable markers, as described above, may be used for the different analytes to prevent one capture zone being confused with another. For example, it is desirable to test for the

presence of HRP II and/or HRP III and aldolase; HRP II and/or HRP III and poly-asparagine proteins; aldolase and poly-asparagine proteins; HRP II and/or HRP III, aldolase, and poly-asparagine proteins and/or; HRP II and aldolase; HRP II and poly-asparagine proteins; HRP II, aldolase, and poly-asparagine proteins.

[0049] As used herein, a subject, is any animal, preferably a mammal. Mammals include, for example, sheep, goats, cows, pigs, horses, humans, and primates. A subject may be susceptible to malaria, e.g., living or visiting a high-risk area. Subject may be identified, selected, and/or diagnosed with malaria by self diagnosis or by a health care professional.

[0050] As used herein, poly-asparagine proteins refer to proteins expressed by *Plasmodium* species that have from between about 5 to about 30; 6 and 25; 10 and 20; or greater than 12 or more (to about 20, 25 or 30) consecutive asparagines in a row. For example, *P. falciparum* has 1473 annotated proteins with 6 asparagines in a row, 1107 proteins with 8 in a row, 733 proteins with 10 in a row, 456 proteins with 12 in a row, 334 proteins with 14 in a row, 246 proteins with 16 in a row, 184 proteins with 18 in a row, 135, proteins with 20 in a row, 114 proteins with 22 in a row. Exemplary poly-asparagine proteins include, for example, the proteins listed in Table 1 obtained from the sequenced genome. *P. falciparum* has multiple repetitive amino acid stretches within its annotated proteins. Notably polyasparagine is not cleaved by any known proteases and, for example, a 12-15 amino acid stretch of poly-asparagines survive intact in urine. As, approximately six amino acid define an immunoglobulin epitope, antibodies to polyasparagine detect many *P. falciparum* poly-asparagine proteins or fragments thereof. Poly asparagine proteins were sequenced in Gardner, MJ, et al. (2002). Genome sequence of the human malaria parasite *Plasmodium falciparum*. Nature 419:498-51 and referenced in Kissinger, J.C., et. al. 2002, "The Plasmodium Genome Database" Nature 419: 490-492 and they include 456 genes in *P. falciparum* and 6 genes in *P. vivax* and 4 genes in *P. knowlesi*, which is incorporated herein by reference in its entirety. Table 1:

***P. FALCIPARUM* GENES WITH 12 OR MORE CONSECUTIVE ASPARAGINES**

MAL13P1.122, MAL13P1.133, MAL13P1.158, MAL13P1.178, MAL13P1.184, MAL13P1.203, MAL13P1.210, MAL13P1.222, MAL13P1.234, MAL13P1.243, MAL13P1.258, MAL13P1.260, MAL13P1.266, MAL13P1.275, MAL13P1.278, MAL13P1.286, MAL13P1.293, MAL13P1.296, MAL13P1.304, MAL13P1.323, MAL13P1.333, MAL13P1.336, MAL13P1.38, MAL13P1.380, MAL13P1.39, MAL13P1.405, MAL13P1.44, MAL13P1.63, MAL13P1.70, MAL13P1.93, MAL7P1.102, MAL7P1.109, MAL7P1.115, MAL7P1.12, MAL7P1.120, MAL7P1.127, MAL7P1.132, MAL7P1.137, MAL7P1.146, MAL7P1.147, MAL7P1.15, MAL7P1.16, MAL7P1.164, MAL7P1.167, MAL7P1.17, MAL7P1.18, MAL7P1.204, MAL8P1.104, MAL8P1.11, MAL8P1.113, MAL8P1.12, MAL8P1.139, MAL8P1.153, MAL8P1.156, MAL8P1.19, MAL8P1.23, MAL8P1.24, MAL8P1.34, MAL8P1.65, MAL8P1.7, MAL8P1.82, MAL8P1.92, PF07_0018, PF07_0022, PF07_0024, PF07_0026, PF07_0028, PF07_0037, PF07_0038, PF07_0042, PF07_0053, PF07_0056, PF07_0061, PF07_0086, PF07_0101, PF07_0116, PF07_0118, PF07_0120, PF07_0126, PF08_0012, PF08_0016, PF08_0020, PF08_0023, PF08_0026, PF08_0028, PF08_0030, PF08_0034, PF08_0040, PF08_0060, PF08_0068, PF08_0096, PF08_0102, PF08_0111, PF08_0122, PF08_0133, PF10_0031, PF10_0044, PF10_0045, PF10_0046, PF10_0057, PF10_0075, PF10_0076, PF10_0078, PF10_0079, PF10_0083, PF10_0115, PF10_0143, PF10_0150, PF10_0175, PF10_0179, PF10_0183, PF10_0197, PF10_0209, PF10_0211, PF10_0213, PF10_0214, PF10_0234, PF10_0265, PF10_0279, PF10_0292, PF10_0296, PF10_0307, PF10_0308, PF10_0320, PF10_0322, PF10_0357, PF10_0361, PF11_0049, PF11_0064, PF11_0076, PF11_0077, PF11_0086, PF11_0089, PF11_0091, PF11_0092, PF11_0101, PF11_0111, PF11_0112, PF11_0127, PF11_0177, PF11_0201, PF11_0207, PF11_0214, PF11_0218, PF11_0240, PF11_0241, PF11_0246, PF11_0276, PF11_0317, PF11_0319, PF11_0324, PF11_0326, PF11_0329, PF11_0341, PF11_0348, PF11_0357, PF11_0371, PF11_0375, PF11_0392, PF11_0395, PF11_0396, PF11_0404, PF11_0418, PF11_0456, PF11_0464, PF11_0468, PF11_0477, PF11_0479, PF11_0480, PF11_0528, PF13_0018, PF13_0035, PF13_0048, PF13_0050, PF13_0078, PF13_0080, PF13_0097, PF13_0106, PF13_0139, PF13_0148, PF13_0153, PF13_0155, PF13_0162, PF13_0163, PF13_0167, PF13_0182, PF13_0187, PF13_0219, PF13_0225, PF13_0235, PF13_0237, PF13_0257, PF13_0267, PF13_0321, PF13_0335, PF13_0339, PF13_0350, PF14_0025, PF14_0031, PF14_0052, PF14_0059, PF14_0063, PF14_0079, PF14_0084, PF14_0101, PF14_0108, PF14_0112, PF14_0114, PF14_0123, PF14_0139, PF14_0143, PF14_0170, PF14_0172, PF14_0173, PF14_0175, PF14_0179, PF14_0184, PF14_0186, PF14_0188, PF14_0195, PF14_0197, PF14_0199, PF14_0228, PF14_0247, PF14_0250, PF14_0252, PF14_0264, PF14_0266, PF14_0277, PF14_0282, PF14_0291, PF14_0293, PF14_0300, PF14_0304, PF14_0315, PF14_0319, PF14_0327, PF14_0342,

(continued)

<i>P. FALCIPARUM</i> GENES WITH 12 OR MORE CONSECUTIVE ASPARAGINES	
5	PF14_0350, PF14_0374, PF14_0412, PF14_0442, PF14_0461, PF14_0463, PF14_0471, PF14_0489, PF14_0494, PF14_0501, PF14_0507, PF14_0515, PF14_0533, PF14_0550, PF14_0558, PF14_0561, PF14_0577, PF14_0594, PF14_0613, PF14_0626, PF14_0649, PF14_0663, PF14_0710, PF14_0711, PF14_0712, PF14_0722, PFA0120 c, PFA0140 c, PFA0165 c, PFA0180w, PFA0215w, PFA0280w, PFA0320w, PFA0410w, PFB0265 c, PFB0280w, PFB0380 c, PFB0460 c, PFB0510w, PFB0540w, PFB0705w, PFB0760w, PFB0800 c, PFB0870w, PF C, 0085 c, PF C, 0235w, PF C, 0245 c, PF C, 0320w, PF C, 0335 c, PF C, 0380w, PF C, 0405 c, PF C, 0425w, PF C, 0440 c, PF C, 0485w, PF C, 0590 c, PF C, 0610 c, PF C, 0750w, PF C, 0760 c, PF C, 0770 c, PF C, 0820w, PF C, 0860w, PF C, 0960 c, PF C, 0965w, PFD0160w, PFD0170 c, PFD0185 c, PFD0200 c, PFD0225w, PFD0285 c, PFD0375w, PFD0385 c, PFD0385w, PFD0535w, PFD0545w, PFD0565 c, PFD0590 c, PFD0710w, PFD0835 c, PFD0840w, PFD0875 c, PFD0885 c, PFD0940w, PFD0985w, PFD1045 c, PFD1100 c, PFD1105w, PFD1115 c, PFD1135 c, PFE0120 c, PFE0130 c, PFE0320w, PFE0430w, PFE0440w, PFE0465 c, PFE0485w, PFE0500 c, PFE0560 c, PFE0570w, PFE0655w, PFE0710w, PFE0935 c, PFE1105 c, PFE1120w, PFE1145w, PFE1185w, PFE1260 c, PFE1325w, PFE1390w, PFE1465w, PFE1555 c, PFF0095 c, PFF0125 c, PFF0195 c, PFF0220w, PFF0295 c, PFF0380w, PFF0390w, PFF0445w, PFF0535 c, PFF0575 c, PFF0590 c, PFF0620 c, PFF0655 c, PFF0670w, PFF0705 c, PFF0765 c, PFF0805 c, PFF0830w, PFF0870w, PFF0910 c, PFF0985 c, PFF1065 c, PFF1145 c, PFF1225 c, PFF1260 c, PFF1365 c, PFF1440w, PFF1460 c, PFF1470 c, PFF1475 c, PFF1485w, PFI0160w, PFI0170w, PFI0185w, PFI0200 c, PFI0225w, PFI0260 c, PFI0285w, PFI0470w, PFI0490 c, PFI0495w, PFI0550w, PFI0710 c, PFI0785 c, PFI0830 c, PFI0970 c, PFI1015w, PFI1085w, PFI1120 c, PFI1155w, PFI1200w, PFI1265w, PFI1280 c, PFI1300 c, PFI1335w, PFI1385 c, PFI1500w, PFI1510w, PFI1590 c, PFL0115w, PFL0170w, PFL0275w, PFL0290w, PFL0350 c, PFL0360 c, PFL0425 c, PFL0545w, PFL0555 c, PFL0600w, PFL0625 c, PFL0675 c, PFL0765w, PFL0855 c, PFL0930w, , PFL0975w, PFL1035w, PFL1075w, PFL1085w, PFL1125w, PFL1130 c, PFL1190 c, PFL1310 c, PFL1335w, PFL1365w, PFL1375w, PFL1395 c, PFL1435 c, PFL1480w, PFL1515 c, PFL1600 c, PFL1620w, PFL1635w, PFL1700 c, PFL1705w, PFL1735 c, PFL1745 c, PFL1795 c, PFL1880w, PFL1900w, PFL1930w, PFL1935 c, PFL1990 c, PFL2165w, PFL2240w, PFL2335w, PFL2390 c, PFL2490 c, PFL2520w
<i>P. VIVAX</i> GENES WITH 12 OR MORE CONSECUTIVE ASPARAGINES	
30	Pv_3915-1-2260-2607; Pv_3915.phat_3 102573318; Pv_5054-6-521-270; Pv_6571-2-545582-545830; Pv_6571.phat_95 102530884; Pv_6737-5-846809-838620; Pv_6737.phat_910 102419958; Pv_6873-6-631938-631687; Pv_6875-3-136785-141518; Pv_6875.phat 31 102294109
<i>P. KNOWLESII</i> GENES WITH 12 OR MORE CONSECUTIVE ASPARAGINES	
35	Pk_1303g03p1 c, -2-2-349; Pk_235 c, 07p1 c, -1-1681-1845; Pk_253g04q1 c, -6-1862-1107; Pk_313d05q1 c, -1-6853-7254; Pk_47b04q1 c, -2-524-679

[0051] Further proteins that may be detected, either alone or in combination in the methods and devices of the invention, include, for example, HRP II, which has gene sequence numbers chr7.phat_42 and chr7.phat_43 94% identity to 95% of P05227; Histidine-rich protein precursor (Clone PFHRP-II) in plasmid.db.; (HRP III has identification MAL13P1.480 histidine-rich protein III) Other genbank numbers for HRP II and III include for example, U69552 HRP III from ITG2 from South America Sullivan MBP; U69551 HRP II from ITG2; X03144 from Stahl NAR 13:7837 1985 HRP III from FC27 that gave rise to D10; M15317 from, Irving & Cross Mol. Biochem. Parasitol. 18 (2), 223-234 (1986) *P. lophurae* duck malaria; X01469 See also Nature 312:616 1984 Ravetch *P. lophurae* duck malaria; M13987 hrp III 7G8 clone Welles Proc. Natl. Acad. Sci. U.S.A. 83 (16), 6065-6069 (1986); M13986 hrp II 7G8 clone Welles Proc. Natl. Acad. Sci. U.S.A. 83 (16), 6065-6069 (1986); K03509 with HRP II PNAS join; AF202093 HRP III FCC1/HN china Zhongguo Jishengchongbing Fangzhi Zazhi 14 (2), 95-99 (2001); AF142344 HRP II from FCC1/HN china; AF314756. 5'UTR of HRP III from Welles group 7G8 clone; EST tags from Sibley 3D7; BU497960 hrp III 3D7; BQ739562 hrp III 3D7; BM275665 gametocyte 3D7 cDNA hrp II); AU088387 hrp ii 3d7 Sugano, S. Gene 200 (1-2), 149-156 (1997); AU088284 hrp ii 3D7 ibid; AU088247 hrp ii 3D7 ibid; AU087127 hrp ii 3D7 ibid. Also include GenBank accession numbers for HRP II AY816237-AY816310 and GenBank accession numbers for HRP III AY821805-AY821825. The gene for aldolase and lactate dehydrogenase are PF14_0425 fructose-bisphosphate aldolase; and PF13_0141 L-lactate dehydrogenase. Additional high abundance glycolytic genes which may appear in bodily fluids and useful in the methods and devices of the invention include, for example, CHR 13 / PF13_0144 oxidoreductase, putative; CHR 10 / PF10_0155 enolase; CHR 6 / PFF1155w hexokinase; PF14_0341 glucose-6-phosphate isomerase; CHR 11 / PF11_0294ATP-dependent phosphofructokinase, putative; CHR 9 / PFI0755c 6-phosphofructokinase, putative; CHR 3 / PFC0831w triosephosphate isomerase, putative; CHR 14 / PF14_0378 triose-phosphate isomerase; CHR 14 / PF14_0598 glyceraldehyde-3-phosphate dehydrogenase; CHR 9 /

PF11105w Phosphoglycerate kinase; CHR 4 / PFD0660w phosphoglycerate mutase, putative; CHR 11 / PF11_0208 phosphoglycerate mutase, putative; CHR 6 / PFF1300w pyruvate kinase, putative; CHR 6 / PFF0895w malate dehydrogenase, putative; CHR 9 / PFI1340w fumarate hydratase, putative; and CHR 10 / PF10_0334 flavoprotein subunit of succinate dehydrogenase.

[0052] The term "sample" as used herein refers to a biological sample selected from nasal fluid, urine, sweat, tears, pus, saliva or sputum. Preferably the biological sample is in liquid form or can be changed into a liquid form. Preferably, the sample is a urine sample. Samples may be buffered or may have their pH altered prior to being applied to the devices or being subjected to the methods of the invention. For example, a urine sample may be buffered with a buffer (e.g., Tris buffer, acid, base, etc) to a pH of between about 4.5 to about 9; to a pH of between about 5 to about 8.9; to a pH of about 7.5 to about 8.5, or to a pH of about 6, 6.6, 7, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, or 9. About, as used in the context of pH or other measurement or parameter described herein refers to the intrinsic variability due to reagents, apparatus, and human error in any measurement or apparatus or human interpretation of a parameter or result.

[0053] Sample volumes can range from between about 0.05 mL to about 20 mL, 0.1 to about 5; 0.1 to about 2; 0.1 to about 1 or 0.1 to about 0.5 mL of sample applied to the assay device. Alternately, enough sample should be applied to the assay device to ensure proper sample flow through the device, and to ensure proper flow of analyte (if present) through the device. Enough sample to ensure the mobility of the mobile labeling reagent is preferable. The amount of sample may depend, in part, on the absorbency of the sample receiving membrane, the absorbent sink, the length of the membranes, and width of the membranes, or the temperature of the device at the time of use and whether or not a reagent is added to the sample prior to the application of the sample to the sample receiving member.

[0054] The sample receiving membrane and the analyte detection membrane may be made of any substance having sufficient porosity to allow capillary action of fluid along its surface and/or through its interior. The porous material of either the sample receiving membrane or the analyte detection membrane should have sufficient porosity to allow movement of antibody- or antigen-coated particles. The porous material of either the sample receiving membrane or the analyte detection membrane should also be wettable by the fluid used in the sample, which contains the analyte to be detected e.g., HRP II and/or III, aldolase, and/or poly-asparagine proteins. Hydrophobicity of a porous material, sometimes referred to herein as a membrane, can be altered to render the membrane hydrophilic for use with aqueous fluid, by processes such as those described in U.S. Pat. No. 4,340,482, or U.S. Pat. No. 4,618,533. Examples of substances which can be used to form a porous material of either the sample receiving membrane or the analyte detection membrane include cellulose, nitrocellulose, cellulose acetate, glass fiber, nylon, polyelectrolyte ion exchange membrane, acrylic copolymer/nylon, and polyethersulfone. In a preferred embodiment, the porous material of either or both the sample receiving membrane and/or the analyte detection membrane are made of nitrocellulose. One skilled in the art will be aware of other porous materials that allow lateral flow.

[0055] The term "lateral flow" refers to liquid flow in which all of the dissolved or dispersed components of the liquid are carried, preferably, at substantially equal rates and with relatively unimpaired flow laterally through the material, as opposed to preferential retention of one or more components. Nitrocellulose has the advantage that proteinaceous reagents, such as an antibody, in the capture situs can be immobilized firmly without prior chemical treatment. If the membrane comprises paper, for example, the immobilization of an antibody in the second zone may be performed by chemical coupling using, for example, CNBr, carbonyldiimidazole, Sodium Periodate, or tresyl chloride.

[0056] Preferably the nitrocellulose sheet has a pore size of at least about 1 micron, even more preferably of greater than about 5 microns, and yet more preferably about 8-12 microns. Very suitable nitrocellulose sheet having a nominal pore size of up to approximately 12 microns, is available commercially from Sartorius GmbH (Goettingen, Germany).

[0057] Optionally, the nitrocellulose or other sample flow sheets may be "backed," e.g., with plastics sheet, to increase its handling strength. This can be manufactured easily by forming a thin layer of nitrocellulose on a sheet of backing material. The actual pore size of the nitrocellulose when backed in this manner will tend to be lower than that of the corresponding unbacked material. Alternatively, a pre-formed sheet of nitrocellulose can be tightly sandwiched between two supporting sheets of solid material, e.g., plastic sheets.

[0058] The term "mobile" as referred to herein means diffusively or non-diffusively attached, or impregnated.

[0059] Preferably the membranes are in the form of a strip or sheet to which during manufacture of the device, one or more reagents can be applied in spatially distinct zones. During use, the liquid sample is allowed to permeate through the sheet or strip from one side or end to another. Reagents that may be applied to the membranes of the invention include a capture reagent, a control reagent, and a mobile labeling reagent. The reagents may be diffusively or non-diffusively bound to the membranes.

[0060] If desired, a device can incorporate two or more discrete bodies of membrane, e.g., separate strips or sheets, some carrying mobile and/or immobilized reagents. These discrete bodies can be arranged in parallel, for example, such that a single application of liquid sample to the device initiates sample flow in the discrete bodies simultaneously. The separate analytical results that can be determined in this way can be used as control results, or if different reagents are used on the different carriers, the simultaneous determination of a plurality of analytes in a single sample can be made. Alternatively, multiple samples can be applied individually to an array of carriers and/or analyzed simultaneously.

[0061] Following the application of a reagent to the capture situs, the remainder of the membrane may then be treated to block any remaining binding sites elsewhere. Blocking can be achieved by treatment with protein (e.g., bovine serum albumin or milk protein), or with polyvinylalcohol or ethanolamine, or any combination of these agents, for example. Between these process steps the membrane may be dried.

[0062] It is preferable that the flow rate of an aqueous sample through the membrane be such that in the untreated material, aqueous liquid migrates at a rate of about 1 to about 3 and preferably about 1.8 cm in approximately 1 minute, but slower or faster flow rates can be used if desired.

[0063] The spatial separation between the sample application membrane and the capture situs, and the flow rate characteristics of the membrane, can be selected to allow adequate reaction times during which the necessary specific binding can occur. Further control over these parameters can be achieved by the incorporation of viscosity modifiers (e.g., sugars and modified celluloses) in the sample to slow down the reagent migration.

[0064] Reagents can be applied to the membrane materials in a variety of ways. Various "printing" techniques are suitable for application of liquid reagents to the membranes, e.g., micro-syringes, pens using metered pumps, direct printing, ink-jet printing, air-brush, and contact (or filament) methods, and any of these techniques can be used in the present context. To facilitate manufacture, the membrane can be treated with the reagents and then subdivided into smaller portions (e.g., small narrow strips each embodying the required reagent-containing zones) to provide a plurality of identical carrier units.

[0065] As used herein, the term "sample receiving membrane," "sample receiving zone, and sample receiving region" are used interchangeably and refer to the portion of the assay device that may be in direct contact with the liquid sample, e.g., it receives the sample to be tested for the analyte in question. The sample can then migrate, for example, by lateral flow from the sample receiving membrane towards the capture situs and optionally to the absorbent sink. Preferably the sample receiving membrane is near one edge of the assay device. The sample receiving membrane is in flow contact with either a labeling reagent membrane or the analyte detection membrane. This could be an overlap, end-to-end connection, stacked or the like. The sample receiving membrane may be impregnated with buffer to neutralize reagents in the sample during the lateral flow immunoassay. The analyte in the sample should be capable of migrating, through lateral flow, with the liquid sample.

[0066] The sample receiving membrane can be made from any bibulous, porous or fibrous material capable of absorbing liquid rapidly. The porosity of the material can be unidirectional (e.g., with pores or fibers running wholly or predominantly parallel to an axis of the membrane) or multidirectional (omnidirectional, so that the membrane has an amorphous sponge-like structure). Porous plastics material, such as polypropylene, polyethylene (preferably of very high molecular weight), polyvinylidene fluoride, ethylene vinylacetate, acrylonitrile and polytetrafluoroethylene can be used. It can be advantageous to pre-treat the membrane with a surface-active agent during manufacture, as this can reduce any inherent hydrophobicity in the membrane and therefore enhance its ability to take up and deliver a moist sample rapidly and efficiently. The sample receiving membranes can also be made from paper or other cellulosic materials, such as nitro-cellulose. Materials that are now used in the nibs of so-called fiber tipped pens are particularly suitable and such materials can be shaped or extruded in a variety of lengths and cross-sections appropriate in the context of the invention. Preferably the material comprising the porous receiving membrane should be chosen such that the membrane can be saturated with aqueous liquid within a matter of seconds. Preferably the material remains robust when moist. The liquid must thereafter permeate freely from the sample receiving membrane into the analyte detection membrane. Suitable materials also include cotton, cellulose, mixed fibers, glass fiber and the like. For example, paper such as 470 and 740-E from Schleicher and Schuell, Keen, N.H., or D28 from Whatman, Fairfield, N.J., can be selected for its high fluid absorption and wicking speed. A more porous material such as glass fiber #66078 from Gelman Sciences, Ann Arbor, Mich., or "POREX" from Porex Technologies, Fairburn, Ga., is suitable for impregnating labeled particles.

[0067] The absorption capacity of the sample receiving membrane may be sufficiently large to absorb the fluids that are delivered to the test strip or membrane. The sample-receiving zone serves to begin the flow of analyte-containing sample, and typically will be constructed of a material that exhibits low analyte retention. The sample-receiving zone may also function as a mechanical immobilization zone, entrapping any undesirable particulates present in the sample.

[0068] Devices may have an absorbent sink in flow contact with at least the analyte detection membrane. The absorbent sink may be formed of any absorbent substance. Examples of substances that may be used include cellulose, cellulose nitrate, cellulose acetate, glass fiber, nylon, polyelectrolyte ion exchange membrane, acrylic copolymer/nylon, Whatman 3MM, polyethersulfone, 470 and 740-E from Schleicher and Schuell, Keen, N.H., or D28 from Whatman, Fairfield, N.J., can be selected for their high fluid absorption and wicking speed.

[0069] The sample receiving membrane, the absorbent sink, the conjugate forming membrane all have a bottom or back surface. The bottom surface may have an adhesive applied to it so that it may be backed by a semi-rigid material to add strength to the membrane.

[0070] The absorbent sink may be made of the same material as the sample receiving membrane or it may be made of a different material. The sink, the sample receiving membrane and the analyte detection membrane may be made of the same material, or they may each be made of different materials.

[0071] "Labeling reagent," as used herein refers to a detectable marker, for example, a colored particle. Examples of particles that may be used include, but are not limited to, colloidal gold particles; colloidal sulphur particles; colloidal selenium particles; colloidal barium sulfate particles; colloidal iron sulfate particles; metal iodate particles; silver halide particles; silica particles; colloidal metal (hydrous) oxide particles; colloidal metal sulfide particles; carbon black particles, colloidal lead selenide particles; colloidal cadmium selenide particles; colloidal metal phosphate particles; colloidal metal ferrite particles; any of the above-mentioned colloidal particles coated with organic or inorganic layers; protein or peptide molecules; liposomes; or organic polymer latex particles, such as polystyrene latex beads.

[0072] One preferred class of particles is colloidal gold particles. Colloidal gold particles may be made by any conventional method, such as the methods outlined in G. Frens, 1973 *Nature Physical Science*, 241:20 (1973). Alternative methods may be described in U.S. Pat. Nos. 5,578,577, 5,141,850; 4,775,636; 4,853,335; 4,859,612; 5,079,172; 5,202,267; 5,514,602; 5,616,467; 5,681,775.

[0073] Another preferred class of particles, are carbon particles, for example carbon black particles. The carbon label may be attached by methods well known to those skilled in the art, including the methods described in US Patent Nos. 5,252,496 and 5,559,041 to Princeton Biomeditech Corporation (Monmouth, NJ), and US Patent Nos. 5,529,901; 5,294,370; 5,348,891 and 5,641,689 to ATO.

[0074] The selection of particle size may be influenced by such factors as stability of bulk sol reagent and its conjugates, efficiency and completeness of release of particles from conjugate pad, speed and completeness of the reaction. Also, the fact that particle surface area may influence steric hindrance between bound moieties may be considered. Particle size may also be selected based on the porosity of the porous material of either the sample receiving membrane or the analyte detection membrane. The particles are preferably sufficiently small to diffuse along the membrane by capillary action of the conjugate buffer.

[0075] Metal sols and other types of colored particles useful as marker substances in immunoassay procedures are also known per se. See, for example, U.S. Pat. No. 4,313,734, Feb. 2, 1982, to Leuvering, the disclosure of which is incorporated herein by reference. For details and engineering principles involved in the synthesis of colored particle conjugates see Horisberger, *Evaluation of Colloidal Gold as a Cytochromic Marker for Transmission and scanning Electron Microscopy*, *Biol. Cellulaire*, 36, 253-258 (1979); Leuvering et al, *Sol Particle Immunoassay*, *J. Immunoassay* 1 (1), 77-91 (1980), and Frens, *Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions*, *Nature, Physical Science*, 241, pp. 20-22 (1973).

[0076] The number of labeling particles present in the porous material of either the sample receiving membrane and/or the analyte detection membrane or test strip may vary, depending on the size and composition of the particles, the composition of the test strip and porous material of either the sample receiving membrane or the analyte detection membrane, and the level of sensitivity of the assay. The number of particles typically ranges between about 1×10^9 and about 1×10^{13} particles, although fewer than about 1×10^9 particles may be used. In a preferred embodiment, the number of particles is about 1×10^{11} particles.

[0077] Particles may be labeled to facilitate detection. Examples of labels include, but are not limited to, luminescent labels; colorimetric labels, such as dyes; fluorescent labels; or chemical labels, such as electroactive agents (e.g., ferrocyanide); enzymes; radioactive labels; or radio frequency labels.

[0078] Indirect labels, such as enzymes, e.g., alkaline phosphatase and horseradish peroxidase, can be used but these usually require the addition of one or more developing reagents such as substrates before a visible signal can be detected. Such additional reagents can be incorporated in the membranes, such that they dissolve or disperse in the aqueous liquid sample. Alternatively, the developing reagents can be added to the sample before contact with the membranes or the membranes can be exposed to the developing reagents after the binding reaction has taken place. Coupling of the label to the mobile labeling reagent may be by covalent bonding, or by hydrophobic bonding. Such techniques are commonplace in the art. In a preferred embodiment, where the label is a direct label such as a colored latex particle, hydrophobic bonding is preferred.

[0079] The presence or intensity of the signal from the label which becomes bound in the capture situs can provide a qualitative or quantitative measurement of analyte in the sample. A plurality of detection or capture zones arranged in series on the membrane, through which the aqueous liquid sample can pass progressively, can also be used to provide a quantitative measurement of the analyte, or can be loaded individually with different specific binding agents to provide a multi-analyte test.

[0080] The reagents that are mobile or releasably bound are capable of dispersing with the liquid sample upon rehydration and are carried by the liquid sample in the lateral flow. The terms "immobile" or "immobilized" as used herein refer to reagents which are attached to the support such that lateral flow of the liquid sample does not affect the placement of the immobile particle in the discrete membrane of the porous material. Such attachment can be through covalent, ionic or hydrophobic means. Those skilled in the art will be aware of means of attachment to immobilize various particles.

[0081] The term "mobile labeling reagent" refers to a suitable reagent labeled with a particle described above. The mobile labeling reagent may be a protein or molecule which recognizes or binds to the analyte in question, and which is conjugated or attached to a substance or particle capable of producing a signal that is detectable by visual or instrumental

means. The attachment to the substance or particle capable of producing a signal may be chemical, covalent or non-covalent, ionic or non-ionic. The particle or molecule recognizing the analyte can be either natural or non-natural, preferably monoclonal, polyclonal, or a fragment of an antibody or a lectin.

[0082] Mobile labeling reagents may be, for example, an antibody to HRP II, HRP III, aldolase, and/or poly-asparagine proteins or fragments or variants thereof. The poly-asparagine repeats of the poly-asparagine proteins are a repeated epitope in *Plasmodium* species. Thus, a sandwich complex can be formed even if the indicator capture reagent and the indicator labeling reagent each contain an antibody to the same epitope (e.g., poly-asparagines).

[0083] The term "labeling reagent membrane" refers to a membrane which contains indicator labeling reagent. The labeling reagent membrane may also contain control labeling reagent. The separate labeling reagent membrane is preferably made of a mixture of cellulose and polyester, or other porous material.

[0084] The term "discrete situs," "capture situs" or "control situs" as used herein refer to a defined area in which either the mobile labeling reagents, the capture reagent, or the control reagent are impregnated or immobilized to the membrane. The situs of the control capture reagent or the capture reagent for the analyte provide a discrete visible signal in a desired geometric shape from which to view the results of the test. For example, if the one mobile labeling reagent is analyte bound to anti-analyte conjugated to Blue latex label, then a discrete blue signal will appear at the discrete capture situs if the indicator capture reagent binds and immobilizes the analyte-labeling reagent complex. If the control labeling reagent is BSA conjugated to a label such as colored latex or gold sol, then a discrete signal will form at the discrete control situs if the control capture reagent has immobilized the BSA-control labeling reagent.

[0085] Control reagents according to the invention may be used to perform a variety of control functions. For example, control reagents may be used to ensure that the assay device is in good working order, they may be used to determine whether the sample has wicked through the membranes properly, they may function to indicate when the assay may be read, e.g., signal the end of the reaction, they may function as internal standards and allow analyte measurement results to be compared between different test strips, and can be useful in demonstrating that the indicator labeling reagent is intact which can provide an indication of the ongoing functionality of the indicator labeling reagent.

[0086] A wide variety of reagents are known in the art that may be used as a control reagent. For example, a naturally occurring or engineered protein may be used to bind unbound mobile labeling reagent. The control reagent may also be one member of a pair of a receptor-ligand pair. Additionally, at least one membrane of the control reagent may be an antigen, another organic molecule, or a hapten conjugated to a protein non-specific for the analyte of interest. Descriptions of other suitable control reagents may be found in U.S. Pat. No. 5,096,837, and include IgG, goat anti-mouse antibodies, other immunoglobulins, bovine serum albumin (BSA), other albumins, casein, and globulin or portions thereof. As a further alternative, a control zone could contain immobilized analyte which will react with excess labeled reagent from the first zone. As one purpose of the control zone is to indicate to the user that the test has been completed, the control zone should be located downstream from the capture situs in which the desired test result is recorded. A positive control indicator therefore tells the user that the sample has permeated the required distance through the test device.

[0087] Desirable characteristics for control reagents include, but are not limited to, stability in bulk, non-specificity for analyte of interest, reproducibility and predictability of performance in test, molecular size, avidity of binding for each other, ability to bind to a membrane, binding availability upon binding to membrane, and immobilization potential.

[0088] The devices of the present invention also may include a procedural control which comprises visible moieties that do not contain the specific binding agent or analyte competitor and that are also carried through to a control area of the capture zone by the liquid flow. These visible moieties are coupled to a control reagent which binds to a specific capture partner and can then be captured in a separate procedural control portion of the capture zone to verify that the flow of liquid is as expected. The visible moieties used in the procedural control may be the same or different color than those used for the test moieties. If different colors are used, ease of reading the results is enhanced. In one preferred embodiment, the procedural control may include a signal that become visible when the sample wicks through the portion of the membrane in the location of the signal. The procedural control may be a line drawn on the housing beneath the membrane, it may be a line on the backing beneath the test strip, or it may be a reagent adhered to, in, on, or within the membrane that becomes visible upon contact with a sample. Alternatively, the control zone can contain an anhydrous reagent that, when moistened, produces a color change or color formation, e.g., anhydrous copper sulphate which will turn blue when moistened by an aqueous sample.

[0089] In a preferred embodiment, the membranes include more than one control zone or situs and may be used to create a calibration curve against which a wide variety of analyte measurement results may be compared. Having the test strip possess more than one control zone allows lateral flow assays to have a wider dynamic range than conventional lateral flow assays. In preferred embodiments, test strips with 2, 3 or more control zones are used with a relative scale methodology, discussed further below, that permits mapping of amounts of control binding pairs detected onto the same scale on which amounts of analyte detected are reported.

[0090] The devices of the invention may also be used to determine quantitatively the amount of analyte in a sample. Once the amount of detectable markers has been measured in each test zone, these measurements may be used to

detect and preferably quantify the amount of analyte present, preferably by also calibrating the test device using the amounts of detectable markers in one or more control zones.

[0091] Examples of detection techniques useful in the invention include seeing a visible signal with the eye and optical methods (light scattering, simple reflectance, luminometer or photomultiplier tube); radioactivity; electrical conductivity; dielectric capacitance; and/or electrochemical detection of released electroactive agents.

[0092] In certain preferred embodiments, the mobile labeling reagent and the immobile capture reagent are antibodies specific for the analyte. Preferably, the mobile labeling reagent and the immobile capture reagent recognize and bind to, for example, different portions of the analyte or to different subunits of the analyte. Antibodies may be polyclonal or monoclonal or fractions thereof. Polyclonal antisera and indeed monoclonal antibodies or fractions thereof having specific binding properties and high affinity for virtually any antigenic substance are known and commercially available or can be produced from stable cell lines using well known cell fusion and screening techniques. The literature is replete with protein immobilization protocols. See, for example, "Laboratory Techniques in Biochemistry and Molecular Biology," Tijssen, Vol. 15, Practice and Theory of Enzyme immunoassays, chapter 13, The Immobilization of Immunoreactants on Solid Phases, pp. 297-328, and the references cited therein.

[0093] Examples of antibodies useful in the methods and device of the invention include the anti-HRP II, anti-HRP III antibodies (e.g., 3A4), anti-aldolase antibodies (e.g., 2E12 or 6B10), anti-poly-asparagine protein antibodies (e.g., antibodies specific for one or more of proteins with poly-asparagines, e.g., specific to the poly asparagine motif.) For example, as is discussed below, the mobile labeling reagent recognizes a poly-asparagine protein, the capture reagent recognizes the anti-poly asparagine capture reagent (e.g., antibody or fragment thereof), and the control agent recognizes the unbound capture reagent.

[0094] As used herein, "capture situs," "detection situs," and "capture zone" are used interchangeably. The immobilized capture reagent is bound at the capture situs on the analyte detection membrane. The capture situs may be impregnated throughout the thickness of the membrane in the capture situs (e.g., throughout the thickness of the sheet or strip if the carrier is in this form). Such impregnation can enhance the extent to which the immobilized reagent can capture any analyte or labeled reagent, present in the migrating sample. Alternately, the immobilized capture reagent is bound only to one or both of the surfaces of the membrane or only impregnates partially the thickness of the membrane.

[0095] The results of an analysis conducted using a device according to the invention may be read in the capture zone by noting the presence or absence of a visible signal at the location of the capture situs or zone. For example, a labeling reagent bound to an analyte will bind to the capture zone and concentrate the label such that it is visible. The use of a control is helpful for indicating the time when test results can be read, as described above. Thus, when the expected signal appears at the control situs, the presence or absence of a color in the capture situs can be noted. The use of different colors for test and control reagents or labels aids in this process.

[0096] Capture reagents may be applied to, for example, the analyte detection membrane via printing, spotting, and like techniques. One skilled in the art having the benefit of this disclosure, would know the appropriate technique for their intended purpose. Optionally, after the application of the capture reagent to the membrane, a blocking agent or agents may be applied or immobilized in situ.

[0097] The capture reagent is immobile, e.g., is not affected by the lateral flow of the liquid sample due to the immobilization to the porous material. The particle or molecule of the indicator capture reagent can be natural, or non-natural, e.g., synthetic. Once the indicator capture reagent binds the analyte-mobile labeling reagent(s) complex it prevents the analyte-mobile labeling reagent from continuing with the lateral flow of the liquid sample.

[0098] The terms "analyte detection membrane," "analyte detection region," and "analyte detection situs," as used herein, refer to the portion of the assay device which is in lateral flow contact with the absorbent sink, and either or both of the the porous material of the sample receiving membrane and/or the porous material of the conjugate forming membrane or region. The contact between the membranes can be an overlap, stacked or end-to-end contact or any other configuration that allows flow contact. The analyte in the sample should be capable of migrating through the membranes with lateral flow, e.g., capillary flow, with the liquid sample. The analyte detection membrane may be made of a porous material. Preferably, the analyte detection membrane is made of nitrocellulose. The analyte detection membrane can contain the mobile labeling reagents, the immobile indicator capture reagent and the immobile control capture reagent. In other embodiments, the analyte detection membrane contains only the immobilized control capture reagent and the capture reagent. In certain embodiments, one or more of the analyte detection membrane, sample receiving membrane, mobile labeling reagent membrane, and absorbent sink are made of the same materials and may be made of a single piece of material that contains zones or regions.

[0099] Features of the analyte detection membrane include its ability to wick fluids and to bind proteins. Exemplary materials include nitrocellulose, nylon or the like. In a preferred embodiment of this invention, the material is nitrocellulose with or without laminated solid support such as polyester. Nitrocellulose is readily available from numerous suppliers, as discussed above.

[0100] The immobilized capture reagent in the capture situs is preferably a highly specific antibody, and more preferably a monoclonal antibody. In one embodiment of the invention involving a sandwich type reaction, the mobile labeling

reagent is also preferably a highly specific antibody, and more preferably a monoclonal antibody.

[0101] The "conjugate forming membrane," "conjugate forming region," and "conjugate forming zone" are used interchangeably herein and may have releasably bound thereto an enzyme-antibody conjugate or particulate moieties which may or may not be visible, and which can be detected if accumulated in the capture zone. The visible moieties, as described above, can be dyes or dyed polymers which are visible when present in sufficient quantity, or can be, and are preferred to be particles such as dyed latex beads, liposomes, or metallic, organic, inorganic or dye solutions, for example, carbon black, dyed or colored cells or organisms, red blood cells and the like. The enzyme-antibody conjugate or particulate moieties used in the assay provide the means for detection of the nature of and quantity of result, and accordingly, their localization in the capture situs or zone may be and is preferably a function of the analyte in the sample. In general, this can be accomplished by coupling the enzyme-antibody conjugate or particulate moieties to a ligand that binds specifically to the analyte, or which competes with analyte for a capture reagent in the capture zone.

[0102] In one approach, the conjugate, or particulate moieties are coupled to a specific binding partner that binds the analyte specifically to form, for example a mobile labeling reagent. For example, if the analyte is an antigen, a labeled antibody specific for this antigen may be used or a labeled immunologically reactive fragments of the antibody, such as Fab'₂, Fab or Fab', or other fragment or binding member of an antibody, may also be used. These mobile labeling reagents may then bind to an analyte in a sample as the sample passes through the labeling zone or situs and are carried into the capture situs by the liquid flow. When the complex reaches the capture zone or situs, it is captured by an analyte-specific capture reagent, such as an antibody. For example, the labeled antibody is an anti- HRP II and/or anti-HRP III antibody and the capture reagent is an anti-antibody antibody. Excess liquid sample may be taken up by the absorbent sink.

[0103] In another approach, the conjugate or particulate moieties are coupled to a labeled ligand which is competitive with analyte for a capture reagent in the capture situs, most typically, other molecules of the analyte itself. Both the analyte from the sample and the labeled competitor bound to the conjugate or particulate moieties are then carried into the capture zone. Both analyte and its competitor then react with the capture reagent, which in this instance is also typically specifically reactive with an analyte and its competitor. The unlabeled analyte thus is able to reduce the quantity of competitor-conjugated conjugate or particulate moieties that are retained in the capture zone. This reduction in retention of the conjugate or particulate moieties becomes a measure of the analyte in the sample.

[0104] The term "adequate mechanical strength," as used herein, refers to a desired support to the assay device so as to function properly. The adequate mechanical strength is the support achieved for the entire assembled assay device so as to function properly in the collection and analysis of the analyte in the liquid sample. The total thickness of all of the layers of the immunoassay device is preferably at least 0.003 inches thick. The total thickness of the immunoassay device consists of the thickness of the backing, the membrane elements, label pads (if desired), and the cover. This minimum total thickness is desired in order to produce the desired adequate mechanical strength or support for the device to function effectively. Adequate mechanic strength, in the test strip embodiment, may be achieved, for example, by the backing.

[0105] The term "plastic material," or "plastic cover," "cover," or "housing" as used herein refers to any plastic material, which can cover the porous material of the device. Preferably, this is Mylar®, however, those skilled in the art will know of various materials that can be used for such purposes. For example, Mylar®, vinyl, other polyesters, polycarbonate, methyl methacrylate polymer, polystyrene, polyethylene, polypropylene, or waxed cardboard. The housing can be one continuous plastic or separate pieces as shown in the Figures. The housing allows the discrete control and discrete capture situs to be viewed and allows for sample to be applied to the sample application membrane. Thus, if the cover is clear then the result can be viewed through the clear cover. If the cover is opaque, then a window, aperture, gap or hole is present in the housing so the results can be viewed.

[0106] The structure of the test strip with a backing may be a laminate structure with the backing adhered to a back of the test strip to provide adequate mechanical strength to the device, e.g., to provide support and strength characteristics of the porous material and overall device such that lateral flow of liquid through the device will not be interrupted, for instance by the collapse or disintegration of the device upon wetting. Additional support for the device during the immunoassay may be provided by the walls of a test tube against which the device may rest during the lateral flow.

[0107] The term "top" refers to the upper surfaces of the membranes of the device, e.g., the top surface of the test strip.

[0108] Test strip backing according to the present invention may be made of, for example, mylar, vinyl, polyester, polycarbonate, methyl methacrylate polymer, polystyrene, polyethylene, polypropylene, and waxed cardboard.

[0109] Alternatively, the backing may be a molded plastic backing. The backing may have a thickness of between about 0.001 inches to about 0.010 inches. The backing material may have an adhesive on one side so as to attach the porous material or membrane. The structure of the test strip with a backing may be a laminate structure with the backing covering the back of the test strip and providing adequate mechanical strength to the device, e.g., providing support and strength characteristics of the porous material and overall device such that lateral flow of liquid through the device will not be interrupted, for instance by the collapse or disintegration of the device upon wetting.

[0110] A method of using the invention includes the steps of applying a sample to an assay device; and observing a

result of the assay. The devices described above may be used in the methods.

[0111] The devices may also be packaged individually or with multiple devices. Each device may be used only one time or they may be designed for multiple uses. The devices may also be packaged as a kit with instruction sheets to inform the user on the proper use of the device.

[0112] Figure 14A is a schematic view of one device according to the invention. The device incorporates a porous analyte detection membrane 5, running almost the length of housing 10 and 11. A procedural control 12 is located on a top surface of the interior of the housing 11. The analyte detection membrane 5 is in lateral flow contact with a conjugate forming membrane 15 and sample receiving membrane 20. The analyte capture situs 24 is also in lateral flow contact with the absorbent sink 25. The sample receiving membrane 20 is located beneath the sample application aperture 30 such that a sample applied through the sample application aperture 30 would be received by the sample receiving membrane 20. The sample would then flow through the conjugate forming membrane and mobilize the mobile labeling reagent contained in, on, releasably immobilized on, or adhered to the conjugate forming membrane. The housing 10 has, in addition to the sample application aperture 30, an observation window 35 positioned to allow a view of the capture situs, the control situs (240 and 246 of Figure 15), and a procedural control 12.

[0113] Figure 14B is a schematic of the top of the housing 10 of Figure 14A. The top of the housing 10 has a sample application aperture 30 and an observation window 35. The observation window may be fitted with a transparent or semi-transparent material that is impervious or semi-impervious to water or it may be an aperture that is not fitted with any materials. Window materials for use in the invention, include, glass, polypropylene, and the like. A person skilled in the art would be able to determine proper window materials for a particular purpose having the benefit of this disclosure.

[0114] Referring to Figure 15, a top view of the lateral flow membranes according to one embodiment of the invention is shown. A sample receiving membrane 220 is in lateral flow contact with a conjugate forming membrane 215, an analyte detection membrane 205, and an absorbent sink 225. The conjugate forming membrane 215 has releasably bound to it a mobile labeling reagent 216 that will be mobilized when in contact with a fluid. The analyte detection membrane 205 has an immobilized capture reagent 240 at a capture situs 241 and a control reagent 245 at a control situs 246.

[0115] Figure 16 illustrates another embodiment of the invention. A top view of the lateral flow membrane according to another embodiment of the invention is shown. A sample receiving membrane 320 is in lateral flow contact with a conjugate forming membrane 315, an analyte detection membrane 305, and an absorbent sink 325. The conjugate forming membrane 315 has releasably bound to it two mobile labeling reagents 316 and 317 that will be mobilized when in contact with a fluid. Each mobile labeling reagent is specific for a different analyte. The analyte detection membrane 305 has two immobilized capture reagents 340 and 342 at capture situs 341 and capture situs 343, respectively. The capture reagents are specific for one or the other of the mobile labeling reagents when bound to an analyte. There is also an immobilized control reagent 345 at a control situs 346 to serve as a control that the assay is functioning.

[0116] Figure 17 depicts a further embodiment of the invention suitable for use as a dipstick wherein the sample to be analyzed is introduced to the lateral flow apparatus by dipping the device into the sample or by flowing the sample over the sample receiving zone of the device. Referring to Figure 17, the test strip 455 has a grip zone 419 to allow handling of the test strip and a sample application zone 420, which is in lateral flow contact with the conjugate forming region 415 containing a labeled specific binding reagent 416. The sample receiving zone is also in flow contact with the absorbent sink 425. The absorbent sink is covered with a covering, for example a plastic film. The film covered absorbent sink may be a grip zone or may be in addition to grip zone 419 as shown. Distal to the conjugate forming region 415 is the capture situs 440 and the control situs 445. Immobilized on the test strip at the capture situs 440 is a capture reagent. The test strip is backed by backing 450 on the bottom surface 456 of the assay strip 455.

[0117] In operation, the sample application zone 420 may be exposed to an aqueous sample, e.g., by dipping the end of the test strip into a sample or by applying a sample to the end of the test strip with a sample applicator. The liquid sample will then permeate the length of test strip 455, for example, by capillary flow. The sample will mobilize the mobile labeling reagent 416 from the conjugate forming region 415 and can bind to an analyte if present in the sample. As the sample permeates the test strip it travels through the capture situs 440 and the control situs 445. At the capture situs, any analyte bound to mobile labeling reagent may bind to the capture reagent to be detected, for example, through a "sandwich" reaction involving an analyte in the sample. Any unbound mobile labeling reagent will pass through the capture situs and may be bound at the control situs 445 by the control reagent.

[0118] Figure 18 is an alternate embodiment of a device according to the invention. A top view of the lateral flow membranes according to one embodiment of the invention is shown. A sample receiving membrane 520 is in lateral flow contact with a conjugate forming membrane 515, an analyte detection membrane 505, and an absorbent sink 525. The conjugate forming membrane 515 has releasably bound to it a mobile labeling reagent 516 that will be mobilized when in contact with a fluid. The analyte detection membrane 505 has an immobilized capture reagent 540 bound there to or located there on at a capture situs 541 and a control reagent 545 at a control situs 546.

[0119] Many circumstances may affect the absolute reactivity of lateral flow assays, including, but not limited to, manufacturing-derived variations, operator induced variations, environmentally induced variations and sample effects.

With conventional lateral flow assays, any of these variations may act to repress or arguably enhance reactivity of one strip over another, resulting in possible false negative or false positive results. Not controlling for these or other variations may result in significant imprecision, non-reproducibility, lack of sensitivity and lack of specificity of the tests.

[0120] Such devices can be provided as kits suitable for home use, comprising a plurality (e.g., two) of devices individually wrapped in moisture impervious wrapping and packaged together with appropriate instructions to the user. The instructions, for example, may provide information on malaria diagnosis, interpretation of the test result and selection of subjects to receive the test.

[0121] Kits of dipstick embodiments may include a plurality of devices, for example, more than one device, e.g., 10, 25, 100, 150 or 1000 devices may be packaged together with instructions for use. Instructions for use may include testing procedures, interpretation procedures, performance characteristics, and information on the test device.

[0122] Kit of devices enclosed in housing according to the invention may be packaged with one or more devices, for example, 5, 10, 25, 30, 100 or 1000 or more devices may be packaged and sold together with instructions for use. Optional other materials provided in the kit may include an control set with negative, positive controls. The instructions may contain information on storage and handling of the devices after purchase and information in the testing procedures.

[0123] Kits may include, for example:

- 25 Test Sticks in a container;
- 25 Test Tubes;
- 25 Transfer Pipettes;
- 25 Capillary Tubes with 1 Capillary Bulb;
- 1 Diluent (contains buffer with 0.2% sodium azide);
- 1 Mono Positive Control (contains rabbit anti-beef stroma in tris buffer with 0.2% sodium azide; and 0.05% gentamycin sulfate preservatives);
- 1 Mono Negative Control (contains goat albumin in tris buffer with 0.2% sodium azide);
- 1 Work Station; and
- 1 Directional Insert

[0124] Other features and advantages of the invention will be apparent from the following detailed description of the presently preferred embodiments of the invention in conjunction with the accompanying drawings and from the claims.

EXAMPLES

[0125] It should be appreciated that the invention should not be construed to be limited to the examples, which are now described; rather, the invention should be construed to include any and all applications provided herein and all equivalent variations within the skill of the ordinary artisan.

EXAMPLE 1

[0126] Of the analyzed, frozen archival from 2001, 12 urine samples with blood films positive for malaria from Zambia, it was found that 10 of 12 (83%) were positive for PfHRP II and/or III by the blood based Binax malaria Pf/Pv NOW® ICT. It was also found that 4 of 12 positive for the pan-species aldolase antigen by the blood Binax malaria test in Figure 1. A commercial test for whole blood detection of parasite lactate dehydrogenase, found that none of the urines were positive for this protein in Figure 2. The antibody in this commercial test kit may recognize only native protein and not be optimal for urine detection.

[0127] A panel of monoclonal antibodies to the antigens detected in the urine were made to verify results outside setting of commercial kits made for blood. Three hybridoma clones were identified, two to HRP II and III and one to a panspecies aldolase. The antibodies detect *P. falciparum* HRP II and III in Figures 3-6 and also the pan *Plasmodium* species aldolase in Figure 7.

[0128] Sequence of representative protein HRP II and III showing a common AHHAHHAA(D,N) (SEQ ID NO: 7) motif in Figure 8 and also below.

PfHRP II

10

15

20

25

30

35

40

45

50

55

17

EP 1 853 914 B1

(continued)

	par/ul	clinical	Malaria urine test		Multistix urine analysis result			
			hrp II	aldolase	blood	prot	pH	spec grav
5	222153	Symptomatic	0.5	0	nil	30	6.5	1.01
	188689	Symptomatic	1	0	1+	nil	6.5	1.01
	89943	Symptomatic	1	0	nil	15	6	1.03
	84000	Symptomatic	0	0	nil	nil	6	1.03
	57900	Symptomatic	0.5	0	nil	1+	5	1.025
10	34000	Symptomatic	2	1	1+	nil	5	1.01
	25600	Symptomatic	2	0.5	nil	nil	5	1.005
	18470	Symptomatic	2	0	2+	nil	5	1.005
	13700	Symptomatic	0.5	0	3+	1+	5	1.03
	13000	Symptomatic	1	0.5	nil	nil	6	1.005
15	10000	Symptomatic	2	0.5	1+	1+	6	1.015
	8539	Symptomatic	2	0.5	nil	nil	6	1.02
	2800	Symptomatic	1	0.5	1+	1+	6	1.03
	960	Symptomatic	2	0.5	nil	1+	6	1.005
		Symptomatic	2	0.5	nil	30	6.5	1.03
20		Symptomatic	2	0.5	1+	30	6	1.03

Table 2B: 2/23 positive in asymptomatic patients =9%

	par/ul	clinical	Malaria urine test		Multistix urine analysis result			
			hrp II	aldolase	blood	prot	pH	spec grav
25	17560	Asymptomatic	0	0	nil	nil	8	1.01
	13508	Asymptomatic	0	0	nil	100	7	1.025
	6545	Asymptomatic	0	0	nil	nil	5	1.03
	6200	Asymptomatic	0	0	2+	nil	7	1.005
	5130	Asymptomatic	0	0	nil	0	8.5	1.005
30	3000	Asymptomatic	0	0	3+	nil	6	1.005
	2400	Asymptomatic	0	0	1+	nil	6	1.02
	2150	Asymptomatic	0	0	nil	nil	8.5	1
	1760	Asymptomatic	0	0	1+	nil	6	1.025
	1708	Asymptomatic	0	0	nil	nil	5	1.03
35	1280	Asymptomatic	0	0	nil	nil	8	1.005
	1200	Asymptomatic	0	0	1+	1+	5	1.015
	1090	Asymptomatic	0	0	3+	200	8.5	1.005
	731	Asymptomatic	0	0	nil	nil	8.5	1.005
	651	Asymptomatic	0	0	3+	300	8.5	1.005
40	615	Asymptomatic	0	0	nil	nil	6	1.03
	475	Asymptomatic	0	0	nil	nil	6	1.03
	456	Asymptomatic	0	0	nil	nil	8.5	1.02
	408	Asymptomatic	0	0	nil	30	8.5	1.005
	385	Asymptomatic	1	0.5	nil	30	7	1.015
45	235	Asymptomatic	0	0	nil	30	8.5	1.005
	200	Asymptomatic	0	0	nil	nil	7.5	1.02
	137	Symptomatic	0.5	0	1+	nil	7	1

[0135] The geometric mean in the symptomatic and asymptomatic children was 22,676 and 1,270 parasites/microliter (ranges-960-232,600 and 137-17,560) respectively. Of the 18 positive urine malaria antigen tests, only 9 were positive for microscopic blood with the Bayer Multistix 10 SG urine dipstick analysis indicating that the urine malaria test works in the absence of detectable hematuria.

[0136] Fever by any mechanism increases protein amounts in urine. Many patients with parasites numbers above 1,000 per microliter were negative on urine test in the absence of fever. This would be the first to distinguish symptomatic and asymptomatic parasitemia which present PCR, and blood immunochromatographic tests cannot do.

References

[0137]

All references are hereby incorporated by reference in their entirety.

Altschul S. et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," *Nucleic Acids Research* 25, 3389-3402 (1997).

APL Technical Digest, vol. 20, no. 3, (1999) This volume contains a series of papers dedicated to description of the APL biological weapons detection effort.

Brown, G., Coppel, R., Vrbova, H., Grummont, R., and Anders R., "P. falciparum: comparative analysis of erythrocyte stage-dependent protein antigens," *Exp. Parasitology* 53, 279-84 (1982).

Cohen, S. and Chait, B., "Mass Spectrometry of Whole Proteins Eluted from SDS-PAGE Electrophoresis Gels," *Analytical Biochemistry* 247, 257-267 (1997).

Cornish, T. and Bryden, W., "Miniature Time-of-Flight Mass Spectrometer for a Field-Portable Biodetection system," *APL Tech. Digest* 20, 335-341 (1999).

Cowman, A., "Functional analysis of drug resistance in *Plasmodium falciparum* in the post-genomic era," *Int. J. Parasitol.* 31, 871-8 (2001).

Dennis, V "Investigations of renal function" in *Cecil Textbook of Medicine* eds Wyngaarden, J, Smith, L and Bennett, C 492-499 (1988)

Fenton, B., Walker, A. and Walliker, D., "Protein variation in clones of *P. falciparum* detected by 2-D electrophoresis," *Mol. Biochem. Parasitology* 16, 173-83 (1985).

Gardner, M. et al., "Chromosome 2 Sequence of the Human Malaria Parasite *P. falciparum*," *Science* 282, 1126-1132 (1998).

Genton, B., Paget, S., Beck, H., Gibson, N., Alpers, M. and Hii, J., "Diagnosis of *Plasmodium Falciparum* Infection Using Parasight-F Test in Blood and Urine of Papua New Guinean Children," *Southeast Asian J. Tropical Medicine Public Health* 29, 35-40 (1998).

Gobom, J., Nordhoff, E., Mirgorodskaya, Ekman, R. and Roepstorff, P., "Sample Purification and Preparation Technique Based on Nano-Scale Reverse-Phase Columns for the Sensitive Analysis of Complex Peptide Mixtures by MALDI-MS," *J. Mass Spectrometry* 34, 105-116 (1999).

Godovac-Zimmermann, J and Brown, L., "Perspectives for Mass Spectrometry and Functional Proteomics," *Mass Spectrometry Reviews* 20, 1-57 (2001).

Hodder, A., Crewther, P., Matthew, M., Reid, G., Moritz, R. et al. "The Disulfide Bond Structure of *Plasmodium* Apical Membrane Antigen-1," *J. Biological Chemistry* 271 29446-29452 (1996).

Howell, S., Withers-Martinez, Kocken, C., Thomas, A. and Blackman, M., "Proteolytic Processing and the Primary Structure of *P. falciparum* Apical Membrane Antigen-1," *J. of Biological Chemistry* 276, 31311-31320 (2001).

Hurst, G., Buchanan, M., Foote, L. and Kennel, S., "Analysis for TNF- α Using Solid Phase Affinity Capture with Radiolabel and MALDI-MS detection," *Analytical Chemistry* 71, 4727-2733 (1999).

Kappe, S. et al., "Exploring the Transcriptome of the Malaria Sporozoite Stage," *Proc. Natl. Academy Sci USA* 98,

9895-9900 (2001).

Karas, M., Bachmann, D., Hillenkamp, F., "Influence of the Wavelength in High-Irradiance UV Laser Desorption Mass Spectrometry of Organic Molecules," *Analytical Chemistry* 57, 2935-2939 (1985).

Karas, M., Bachmann, D., Bahr, U., and Hillenkamp, F., "Matrix-Assisted Ultraviolet Laser Desorption of Non-volatile Compounds," *International Journal of Mass Spectrometry Ion Processes* 78, 53-68 (1987).

Karas, M and Hillenkamp, F., "Laser Desorption of Proteins with Molecular Masses Exceeding 10 kDa," *Analytical Chemistry* 60, 2299-2301 (1988).

Katzin, A., Kimura, E., Alexandre, C. and Val Ramos, A., "Detection of Antigens in Urine of Patients with Acute Falciparum and Vivax Malaria Infections," *Am. J. Trop. Med. Hyg.* 45, 453-462 (1991).

Keough T., Youngquist, R. and Lacey, M., "A method for high sensitivity peptide sequencing using postsource decay MALDI-MS," *Proc. Natl. Academy Sci. USA* 96, 7131-7136 (1999).

Kussmann, M., Nordhoff, E., Rahbek-Nielsen, H., Haebel, S., Rossel-Larsen M. et al., "MALDI-MS Sample Preparation Techniques Designed for Various Peptide and Protein Analytes," *J. Mass Spectrometry* 32, 593-601 (1997).

Militao, D.N., Camargo, L.M., Katzin, A.M., "Detection of Antigens in the Urine of Patients with Acute Plasmodium vivax Malaria," *Experimental Parasitology* 76, 115-120 (1993).

Nelson, R., Jarvik, J., Taillon, B. and Tubbs, K., "BIA/MS of Epitope-Tagged Peptides Directly from E. coli Lysate: Multiplex Detection and Protein Identification at Low-Femtomole to Subfemtomole Levels," *Analytical Chemistry* 71, 2858-2865 (1999).

Neubauer G., King, A., Rappsilber, J., Calvio, C., Watson, M., Ajuh, P., Sleeman, J., Lamond, A. and Mann, M., "Mass spectrometry and EST-database searching allows characterization of the multi-protein spliceosome complex," *Nature Genetics* 20, 46-50 (1998).

Pachebat, J., Ling, I., Grainger, M., Trucco, C. et al., "The 22 kDa component of the protein complex on the surface of P. falciparum merozoites is derived from a larger precursor, merozoite surface protein 7," *Molecular & Biochemical Parasitology* 117, 83-89 (2001).

Pandey, A. and Mann, M., "Proteomics to study genes and genomes," *Nature* 405, 837-846 (2000).

Peter, J., Unverzagt, C., Lenz, H. and Hoesel, W., "Purification of Prostate-Specific Antigen from Human Serum by Indirect Immunosorption and Elution with a Hapten," *Analytical Biochemistry* 273, 98-104 (1999).

Pinswasdi C., Thaithong, S., Beale, G., Fenton, B., Webster, H. and Pavanand, K., "Polymorphism of proteins in malaria parasites following mefloquine treatment," *Mol. Biochem. Parasitol.* 23, 159-64 (1987).

Qian, X., Zhou, W., Khaledi, M. and Tomer, K., "Direct analysis of the products of sequential cleavages of peptides and proteins affinity bound to immobilized metal ion beads by MALDI-TOF-MS," *Analytical Biochemistry* 274, 174-180 (1999).

Rabilloud, T., Blisnick, T., Heller, M., Luche S., Aebersold, R., Lunardi, J. and Braun-Breton, C. "Analysis of membrane proteins by two-dimensional electrophoresis: Comparison of the proteins extracted from normal or P. falciparum infected erythrocyte ghosts," *Electrophoresis* 20, 3603-3610 (1999).

Rodriguez-Del Valle, M., Quakyi, I.A., Amuesi, J., Quaye, J.T., Nkrumah, F.K. and Taylor, D., "Detection of Antigens and Antibodies in the Urine of Humans with Plasmodium falciparum Malaria," *J. Clin. Microbiology* 29, 1236-1242 (1991).

Sagoe-Moses, C Pearson, R Perry, J and Jagger, J "Risks to Healthcare Workers in Developing Countries" *New Eng. J Med.* 345:538-541 (2001)

Schriemer, D. and Li, L., "Combining Avidin-Biotin Chemistry with MALDI-MS," Analytical Chem. 68, 3382-3387 (1996).

Seesod, N., Lunderberg, J., Hedrum, A., Aslund, L., Holder, A., Thaithong, S. and Uhlen, M., Immunomagnetic purification to facilitate DNA diagnosis of *P. falciparum*," J. Clin. Microbiology 31, 2715-9 (1993).

Sherman, I "Carbohydrate Metabolism of Asexual Stages" in Malaria ed Sherman, I p 575 ASM (1998)

Shevchenko, A., Jensen, O., Podtelejnikov, et al., "Linking genome and proteome by mass spectrometry: Large scale identification of yeast proteins from two dimensional gels," Proc. Natl. Academy Science USA 93, 14440-14445 (1996a)

Shevchenko, A., Wilm, M., Vorm, O. and Mann, M., "Mass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels," Analytical Chemistry 68, 850-858 (1996b).

Spengler, B. "Post-source Decay Analysis in MALDI-MS of Biomolecules," J. Mass Spectrometry 32, 1019-1036 (1997).

Tait, A. "Analysis of protein variation in *P. falciparum* by 2D electrophoresis," Mol. Biochem. Parasitology 2, 205-218 (1981).

Wilkins, M., Proteome Research: New Frontiers in Functional Genomics, eds. Wilkins, M.R., Williams, K.L, Appel, R.D. and Hochstrasser, D.F., Springer-Verlag, Heidelberg, Germany (1997).

Ethiop Med J. 1984 Jul;22(3):119-27. Detection of malaria antigens in urine, using a solid-phase radioimmunoassay: preliminary study.

Am J Trop Med Hyg. 1991 Oct;45(4):453-62. Detection of antigens in urine of patients with acute falciparum and vivax malaria infections.

Exp Parasitol. 1993 Mar;76(2):115-20 Detection of antigens in the urine of patients with acute Plasmodium vivax malaria.

Southeast Asian J Trop Med Public Health. 1998 Mar;29(1):35-40. Diagnosis of Plasmodium falciparum infection using ParaSight(R)-F test in blood and urine of Papua New Guinean children.

J Travel Med. 1996 Sep 1;3(3): 172-173. Rapid Manual Diagnosis of Plasmodium falciparum Malaria Using ParaSight-F Dipsticks Applied to Human Blood and Urine.

J Clin Microbiol. 1991 Jun;29(6):1236-42. Detection of antigens and antibodies in the urine of humans with Plasmodium falciparum malaria

Mu J, Duan J, Makova KD, Joy DA, Huynh CQ, Branch OH, Li WH, Su XZ.

Chromosome-wide SNPs reveal an ancient origin for *Plasmodium falciparum*.

Nature. 2002; 418:323-6, describes *P.falciparum* from all over the world with a tree showing genetic distance between strains.

Claims

1. A method of diagnosing a *Plasmodium* infection in a subject, comprising detecting the presence or absence of one or more poly asparagine proteins being expressed by a *Plasmodium* species and comprising 12 or more consecutive asparagine amino acid residues in a sample taken from a subject selected from nasal fluid, urine, sweat, tears, pus, saliva or sputum, wherein the presence of one or more poly asparagine proteins is indicative of a *Plasmodium* infection.

2. The method of claim 1, wherein the poly asparagine proteins comprise from 12 to 25 consecutive asparagine amino acid residues.

3. The method of claim 1, wherein the sample is a urine sample.

4. The method of claim 1, wherein if the sample is urine, the sample is buffered to a pH of between about 4 to about 9.

5. The method of claim 1, wherein if the sample is urine, the sample is buffered to a pH of about 7.5 to about 8.5.

6. The method of claim 1, further comprising detecting the presence or absence of one or more additional *Plasmodium* proteins or fragments thereof.

7. The method of claim 6, wherein the one or more additional proteins comprise histidine rich protein II (HRP II, HRP III), aldolase, lactate dehydrogenase, one or more poly-asparagine proteins or fragments or variants thereof.

8. The method of claim 1 or 7, wherein the *Plasmodium* is one or more of *Plasmodium falciparum*, *Plasmodium yoelii*, *Plasmodium knowlesi*, *Plasmodium brasilaneum*, *Plasmodium ovale*, *Plasmodium chabaudi*, *Plasmodium vivax*, *Plasmodium malariae*, *Plasmodium berghei*, *Plasmodium reichenowi*, *Plasmodium gallinaceum*.

9. A method of differentially diagnosing symptomatic *Plasmodium* infection from asymptomatic *Plasmodium* infection and no infection, comprising:

detecting the presence or absence of one or more poly asparagine proteins in a sample taken from a subject, selected from nasal fluid, urine, sweat, tears, pus, saliva or sputum, with a lateral flow device, wherein the poly asparagine proteins are expressed by a *Plasmodium* species and comprise 12 or more consecutive asparagine amino acid residues, and correlating a lack of detection of poly asparagine proteins with asymptomatic disease or no infection.

10. A method of differentially diagnosing symptomatic *Plasmodium* infection from asymptomatic *Plasmodium* infection and no infection, comprising:

detecting the level of one or more poly asparagine proteins in a sample taken from a subject, selected from nasal fluid, urine, sweat, tears, pus, saliva or sputum, with a lateral flow device, wherein the poly asparagine proteins are expressed by a *Plasmodium* species and comprise 12 or more consecutive asparagine amino acid residues, and correlating a low level or lack of detection poly asparagine proteins with asymptomatic disease or no infection.

11. The method of any one of claims 1, 9 or 10 wherein the detecting is with a lateral flow device, mass spectrometry, immunoassay, or colorimetric assay.

12. The method of claim 11, wherein the immunoassay is selected from one or more of ELISA, immunoprecipitation, immunodiffusion, radioimmunoassay, immunofluorescence, or lateral flow assay.

13. A method of detecting the presence of a *Plasmodium* analyte in a sample, comprising:

applying a sample, selected from nasal fluid, urine, sweat, tears, pus, saliva or sputum, to an assay device, wherein the assay device comprises a sample receiving membrane which conducts flow of a liquid sample in flow contact with an analyte detection membrane which conducts flow of the sample, wherein the analyte detection membrane comprises a conjugate forming membrane comprising a mobile labeling reagent at a labeling situs, and an immobile capture reagent at a capture situs, wherein the labeling reagent is capable of forming a complex with a poly-asparagine protein and the capture reagent is capable of binding a poly-asparagine protein-labeling reagent complex, wherein the poly asparagine proteins are expressed by a *Plasmodium* species and comprise 12 or more consecutive asparagine amino acid residues, wherein said liquid sample flows from the sample receiving membrane and mixes with the mobile labeling reagent to move the mobile labeling reagent toward the control situs, and observing a result of the assay.

14. The method of claim 13, wherein the sample is urine.

15. The method of claim 13, wherein the flow is lateral flow.

16. The method of claim 13, wherein the assay device further comprises a second mobile labeling reagent at the labeling situs, and a second immobile capture reagent at the capture situs, wherein the second mobile labeling reagent is capable of forming a complex with HRP II, HRP III or a fragment or variant thereof and the capture reagent is capable of binding HRP II, HRP III -labeling reagent complex.

17. The method of claim 13, wherein the assay device further comprises a second mobile labeling reagent at the labeling situs, and a second immobile capture reagent at the capture situs, wherein the second mobile labeling reagent is capable of forming a complex with aldolase or a fragment or variant thereof and the capture reagent is capable of binding aldolase-labeling reagent complex.

18. The method of claim 13, wherein the assay device further comprises a second mobile labeling reagent at the labeling situs, and a second immobile capture reagent at the capture situs, wherein the second mobile labeling reagent is capable of forming a complex with lactate dehydrogenase or a fragment or variant thereof and the capture reagent is capable of binding lactate dehydrogenase-labeling reagent complex.

19. A method of detecting the presence of a *Plasmodium* analyte in a sample, selected from nasal fluid, urine, sweat, tears, pus, saliva or sputum, comprising:

applying the sample to an assay device,
wherein the assay device comprises a sample receiving membrane which conducts flow of a liquid sample in
flow contact with an analyte detection membrane which conducts flow of the sample,
wherein the analyte detection membrane comprises a conjugate forming membrane comprising a first and a
second mobile labeling reagent at a labeling situs, and a first and a second immobile capture reagent at a
capture situs,
wherein the first labeling reagent is capable of forming a complex with a HRP II, HRP III or a fragment or variant
thereof; the second labeling reagent is capable of forming a complex with a poly asparagine protein; the first
capture reagent is capable of binding a HRP II, HRP III-labeling reagent complex; and the second capture
reagent is capable of binding a poly asparagine protein-labeling reagent complex, and
wherein said liquid sample flows from the sample receiving membrane and mixes with the mobile labeling
reagent to move the mobile labeling reagent toward the control situs, and
observing a result of the assay,
wherein the poly asparagine proteins are expressed by a *Plasmodium* species and comprise 12 or more con-
secutive asparagine amino acid residues.

20. The method of claim 19, wherein the sample is urine.

21. The method of claim 13 or 19, wherein an accumulation of particles at the capture situs produces an indicative signal of the presence of the *Plasmodium* analyte in the sample.

Patentansprüche

1. Verfahren zum Diagnostizieren einer *Plasmodium*-Infektion bei einem Subjekt, das Detektieren des Vorliegens oder der Abwesenheit eines Polyasparaginproteins oder mehrerer Polyasparaginproteine, die durch eine Plasmodium-Spezies exprimiert werden und 12 oder mehr aufeinanderfolgende Asparaginaminosäurereste umfassen, in einer Probe, die von einem Subjekt entnommen wurde, ausgewählt aus Nasenflüssigkeit, Urin, Schweiß, Tränen, Eiter, Speichel oder Sputum, umfasst, wobei das Vorliegen eines Polyasparaginproteins oder mehrerer Polyasparaginproteine für eine *Plasmodium*-Infektion indikativ ist.

2. Verfahren gemäß Anspruch 1, wobei die Polyasparaginproteine 12 bis 25 aufeinanderfolgende Asparaginaminosäurereste umfassen.

3. Verfahren gemäß Anspruch 1, wobei die Probe eine Urinprobe ist.

4. Verfahren gemäß Anspruch 1, wobei, wenn die Probe Urin ist, die Probe auf einen pH von zwischen etwa 4 und etwa 9 gepuffert wird.

5. Verfahren gemäß Anspruch 1, wobei, wenn die Probe Urin ist, die Probe auf einen pH von etwa 7,5 bis etwa 8,5 gepuffert wird.

6. Verfahren gemäß Anspruch 1, das außerdem Detektieren des Vorliegens oder der Abwesenheit von einem oder mehreren zusätzlichen *Plasmodium*-Protein(en) oder Fragmenten davon umfasst.

7. Verfahren gemäß Anspruch 6, wobei das eine zusätzliche Protein oder die mehreren zusätzlichen Proteine Histiidinreiches Protein II (HRP II, HRP III), Aldolase, Laktatdehydrogenase, ein oder mehrere Polyasparaginprotein(e) oder Fragmente oder Varianten davon umfasst/umfassen.

8. Verfahren gemäß Anspruch 1 oder 7, wobei *Plasmodium* eins oder mehrere von *Plasmodium falciparum*, *Plasmodium yoelii*, *Plasmodium knowlesi*, *Plasmodium brasilaneum*, *Plasmodium ovale*, *Plasmodium chabaudi*, *Plasmodium vivax*, *Plasmodium malariae*, *Plasmodium berghei*, *Plasmodium reichenowi*, *Plasmodium gallinaceum* ist.

9. Verfahren zum differentiellen Diagnostizieren symptomatischer *Plasmodium*-Infektion zur Unterscheidung von asymptomatischer *Plasmodium*-Infektion und keiner Infektion, umfassend:

Detektieren des Vorliegens oder der Abwesenheit eines Polyasparaginproteins oder mehrerer Polyasparaginproteine in einer Probe, die von einem Subjekt entnommen wurde, ausgewählt aus Nasenflüssigkeit, Urin, Schweiß, Tränen, Eiter, Speichel oder Sputum, mit einer Lateralströmungsvorrichtung, wobei die Polyasparaginproteine durch eine *Plasmodium*-Spezies exprimiert werden und 12 oder mehr aufeinanderfolgende Asparaginaminosäurereste umfassen, und Korrelieren eines Fehlens der Detektion von Polyasparaginproteinen mit asymptomatischer Erkrankung oder keiner Infektion.

10. Verfahren zum differentiellen Diagnostizieren einer symptomatischen *Plasmodium*-Infektion zur Unterscheidung von asymptomatischer *Plasmodium*-Infektion und keiner Infektion, umfassend:

Detektieren des Levels eines Polyasparaginproteins oder mehrerer Polyasparaginproteine in einer Probe, die von einem Subjekt entnommen wurde, ausgewählt aus Nasenflüssigkeit, Urin, Schweiß, Tränen, Eiter, Speichel oder Sputum, mit einer Lateralströmungsvorrichtung, wobei die Polyasparaginproteine durch eine *Plasmodium*-Spezies exprimiert werden und 12 oder mehr aufeinanderfolgende Asparaginaminosäurereste umfassen, und Korrelieren eines niedrigen Levels oder eines Fehlens der Detektion von Polyasparaginproteinen mit asymptomatischer Erkrankung oder keiner Infektion.

11. Verfahren gemäß einem der Ansprüche 1, 9 oder 10, wobei das Detektieren mit einer Lateralströmungsvorrichtung, mit Massenspektrometrie, einem Immunoassay oder einem kolorimetrischen Assay erfolgt.

12. Verfahren gemäß Anspruch 11, wobei der Immunoassay ausgewählt ist aus einem oder mehreren von ELISA, Immunpräzipitation, Immundiffusion, Radioimmunoassay, Immunfluoreszenz oder Lateralströmungs-Assay.

13. Verfahren zum Detektieren des Vorliegens eines *Plasmodium*-Analyten in einer Probe, umfassend:

Auftragen einer Probe, ausgewählt aus Nasenflüssigkeit, Urin, Schweiß, Tränen, Eiter, Speichel oder Sputum, auf eine Assayvorrichtung, wobei die Assayvorrichtung eine Proben-aufnehmende Membran umfasst, welche den Strom einer Flüssigkeitsprobe in Strömungskontakt mit einer Analytendetektionsmembran, welche den Strom der Probe leitet, leitet, wobei die Analytendetektionsmembran eine Konjugatbildende Membran umfasst, welche ein mobiles Markierungsreagens an einer Markierungsstelle und ein immobiles Fangreagens an einer Fangstelle umfasst, wobei das Markierungsreagens geeignet ist, einen Komplex mit einem Polyasparaginprotein zu bilden, und das Fangreagens geeignet ist, einen Polyasparagin-Markierungsreagens-Komplex zu binden, wobei die Polyasparaginproteine durch eine *Plasmodium*-Spezies exprimiert werden und 12 oder mehr aufeinanderfolgende Asparaginaminosäurereste umfassen, wobei die Flüssigkeitsprobe aus der Probeaufnehmenden Membran fließt und sich mit dem mobilen Markie-

rungsreagens vermischt, um das mobile Markierungsreagens in Richtung der Kontrollstelle zu bewegen, und Betrachten des Resultates des Assays.

14. Verfahren gemäß Anspruch 13, wobei die Probe Urin ist.

15. Verfahren gemäß Anspruch 13, wobei der Strom ein Lateralstrom ist.

16. Verfahren gemäß Anspruch 13, wobei die Assayvorrichtung außerdem ein zweites mobiles Markierungsreagens an der Markierungsstelle und ein zweites immobiles Fangreagens an der Fangstelle umfasst, wobei das zweite mobile Markierungsreagens geeignet ist, einen Komplex mit HRP II, HRP III oder einem Fragment oder einer Variante davon zu bilden, und das Fangreagens geeignet ist, einen HRP-II-, HRP-III-Markierungsreagens-Komplex zu binden.

17. Verfahren gemäß Anspruch 13, wobei die Assayvorrichtung außerdem ein zweites mobiles Markierungsreagens an der Markierungsstelle und ein zweites immobiles Fangreagens an der Fangstelle umfasst, wobei das zweite mobile Markierungsreagens geeignet ist, einen Komplex mit Aldose oder einem Fragment oder einer Variante davon zu bilden, und das Fangreagens dazu geeignet ist, einen Aldolase-Markierungsreagens-Komplex zu binden.

18. Verfahren gemäß Anspruch 13, wobei die Assayvorrichtung außerdem ein zweites mobiles Markierungsreagens an der Markierungsstelle und ein zweites immobiles Fangreagens an der Fangstelle umfasst, wobei das zweite mobile Markierungsreagens geeignet ist, einen Komplex mit Laktatdehydrogenase oder einem Fragment oder einer Variante davon zu bilden, und das Fangreagens geeignet ist, einen Laktatdehydrogenase-Markierungsreagens-Komplex zu binden.

19. Verfahren zum Detektieren des Vorliegens eines *Plasmodium*-Analyten in einer Probe, ausgewählt aus Nasenflüssigkeit, Urin, Schweiß, Tränen, Eiter, Speichel oder Sputum, umfassend:

Auftragen der Probe auf eine Assay-Vorrichtung,

wobei die Assay-Vorrichtung eine Probe-aufnehmende Membran umfasst, welche einen Strom einer Flüssigkeitsprobe in Strömungskontakt mit einer Analytendetektionsmembran, welche den Strom der Probe leitet, leitet, wobei die Analytendetektionsmembran eine Konjugatbildende Membran umfasst, die ein erstes und ein zweites mobiles Markierungsreagens an einer Markierungsstelle und ein erstes und zweites immobiles Fangreagens an einer Fangstelle umfasst,

wobei das erste Markierungsreagens geeignet ist, einen Komplex mit einem HRP II, HRP III oder einem Fragment oder einer Variante davon zu bilden; das zweite Markierungsreagens geeignet ist, einen Komplex mit einem Polyasparaginprotein zu bilden; das erste Fangreagens geeignet ist, einen HRP-II-, HRP-III-Markierungsreagens-Komplex zu binden, und das zweite Fangreagens geeignet ist, einen Polyasparaginprotein-Markierungsreagens-Komplex zu binden, und

wobei die Flüssigkeitsprobe aus der Probeaufnehmenden Membran strömt und sich mit dem mobilen Markierungsreagens mischt, um das mobile Markierungsreagens in Richtung der Kontrollstelle zu bewegen und Betrachten des Resultates des Assays,

wobei die Polyasparaginproteine durch eine *Plasmodium*-Spezies exprimiert werden und 12 oder mehr aufeinanderfolgende Asparaginaminosäurereste umfassen.

20. Verfahren gemäß Anspruch 19, wobei die Probe Urin ist.

21. Verfahren gemäß Anspruch 13 oder 19, wobei eine Ansammlung von Partikeln an der Fangstelle ein Hinweissignal für das Vorliegen des *Plasmodium*-Analyten in der Probe produziert.

Revendications

1. Procédé de diagnostic d'une infection par Plasmodium chez un sujet, comprenant la détection de la présence ou de l'absence d'une ou plusieurs protéine(s) de polyasparagine étant exprimée(s) par une espèce de Plasmodium et comprenant 12 ou plus résidus successifs d'acide aminé asparagine dans un échantillon, prélevé d'un sujet, choisi parmi le fluide nasal, l'urine, la sueur, les larmes, le pus, la salive ou le crachat, dans lequel la présence d'une ou plusieurs protéine(s) de polyasparagine est indicative d'une infection de Plasmodium.

2. Procédé selon la revendication 1, dans lequel les protéines de polyasparagine comprennent de 12 à 25 résidus

successifs d'acide aminé asparagine.

3. Procédé selon la revendication 1, dans lequel l'échantillon est un échantillon d'urine.

4. Procédé selon la revendication 1, dans lequel, si l'échantillon est de l'urine, l'échantillon est tamponné à un pH compris entre environ 4 et environ 9.

5. Procédé selon la revendication 1, dans lequel, si l'échantillon est de l'urine, l'échantillon est tamponné à un pH d'environ 7,5 à environ 8,5.

6. Procédé selon la revendication 1, comprenant en outre la détection de la présence ou de l'absence d'une ou plusieurs autres protéine(s) de Plasmodium ou des fragments de celles-ci.

7. Procédé selon la revendication 6, dans lequel l'une ou les plusieurs autres protéine(s) comprennent la protéine riche en histidine II (HRP II, HRP III), d'aldolase, la lactate-déshydrogénase, une ou plusieurs protéine(s) de polyasparagine ou des fragments ou des variantes de celles-ci.

8. Procédé selon la revendication 1 ou 7, dans lequel le Plasmodium est un ou plusieurs de *Plasmodium falciparum*, *Plasmodium yoelii*, *Plasmodium knowlesi*, *Plasmodium brasilaneum*, *Plasmodium ovale*, *Plasmodium chabaudi*, *Plasmodium vivax*, *Plasmodium malariae*, *Plasmodium berghei*, *Plasmodium reichenowi*, *Plasmodium gallinaceum*.

9. Procédé de diagnostic différentiel d'une infection symptomatique par Plasmodium en différenciant d'une infection asymptomatique par Plasmodium et de l'absence d'une infection, comprenant:

la détection de la présence ou de l'absence d'une ou plusieurs protéine(s) de polyasparagine dans un échantillon, prélevé d'un sujet, choisi parmi le fluide nasal, l'urine, la sueur, les larmes, le pus, la salive ou le crachat en utilisant un dispositif à écoulement latéral,

dans lequel les protéines de polyasparagine sont exprimées par une espèce de Plasmodium et comprennent 12 ou plus résidus successifs d'acide aminé asparagine, et

la corrélation d'une absence de détection des protéines de polyasparagine avec une maladie asymptomatique ou avec l'absence d'une infection.

10. Procédé de diagnostic différentiel pour diagnostiquer une infection symptomatique par Plasmodium en différenciant d'une infection asymptomatique par Plasmodium et de l'absence d'une infection, comprenant:

la détection du niveau d'une ou plusieurs protéine(s) de polyasparagine dans un échantillon, prélevé d'un sujet, choisi parmi le fluide nasal, l'urine, la sueur, les larmes, le pus, la salive ou le crachat en utilisant un dispositif à écoulement latéral, dans lequel les protéines de polyasparagine sont exprimées par une espèce de Plasmodium et comprennent 12 ou plus résidus successifs d'acide aminé asparagine, et

la corrélation d'un faible niveau ou de l'absence de détection des protéines de polyasparagine avec une maladie asymptomatique ou avec l'absence d'une infection.

11. Procédé selon l'une quelconque des revendications 1, 9 ou 10, dans lequel la détection est effectuée avec un dispositif à écoulement latéral, la spectrométrie de masse, un dosage immunologique ou un dosage colorimétrique.

12. Procédé selon la revendication 11, dans lequel le dosage immunologique est choisi parmi un ou plusieurs d'ELISA, immunoprécipitation, immunodiffusion, dosage radio-immunologique, immunofluorescence ou dosage à écoulement latéral.

13. Procédé de détection de la présence d'un analyte de Plasmodium dans un échantillon, comprenant:

l'application d'un échantillon, choisi parmi le fluide nasal, l'urine, la sueur, les larmes, le pus, la salive ou le crachat, à un dispositif de dosage,

dans lequel le dispositif de dosage comprend une membrane recevant l'échantillon qui conduit l'écoulement d'un échantillon liquide en contact d'écoulement avec une membrane de détection d'analyte qui conduit l'écoulement de l'échantillon;

dans lequel la membrane de détection d'analyte comprend une membrane formant un conjugué et comprenant un réactif de marquage mobile à un situs de marquage et un réactif de capture à un situs de capture;

dans lequel le réactif de marquage est capable de former un complexe avec une protéine de polyasparagine, et le réactif de capture est capable de lier un complexe protéine de polyasparagine-réactif de marquage, dans lequel les protéines de polyasparagine sont exprimées par Plasmodium et comprennent 12 ou plus résidus successifs d'acide aminé asparagine,
 dans lequel l'échantillon liquide s'écoule d'une membrane recevant l'échantillon et se mélange avec le réactif de marquage mobile pour déplacer le réactif de marquage mobile en direction du situs de contrôle, et l'observation du résultat du dosage.

14. Procédé selon la revendication 13, dans lequel l'échantillon est de l'urine.

15. Procédé selon la revendication 13, dans lequel l'écoulement est un écoulement latéral.

16. Procédé selon la revendication 13, dans lequel le dispositif de dosage comprend en outre un deuxième réactif de marquage mobile au situs de marquage et un deuxième réactif de capture immobile au situs de capture, le deuxième réactif de marquage mobile étant capable de former un complexe avec HRP II, HRP III ou un fragment ou une variante de celles-ci et le réactif de capture étant capable de lier un complexe HRP II-, HRP III-réactif de marquage.

17. Procédé selon la revendication 13, dans lequel le dispositif de dosage comprend en outre un deuxième réactif de marquage mobile au situs de marquage et un deuxième réactif de capture immobile au situs de capture, le deuxième réactif de marquage mobile étant capable de former un complexe avec l'aldolase ou un fragment ou une variante de celle-ci, et le réactif de capture étant capable de lier un complexe aldolase-réactif de marquage.

18. Procédé selon la revendication 13, dans lequel le dispositif de dosage comprend en outre un deuxième réactif de marquage mobile au situs de marquage et un deuxième réactif de capture immobile au situs de capture, le deuxième réactif de marquage mobile étant capable de former un complexe avec la lactate-déshydrogénase ou un fragment ou une variante de celle-ci, et le réactif de capture étant capable de lier un complexe lactate-déshydrogénase-réactif de marquage.

19. Procédé de détection de la présence d'un analyte de Plasmodium dans un échantillon, choisi parmi le fluide nasal, l'urine, la sueur, les larmes, le pus, la salive ou le crachat, comprenant:

l'application de l'échantillon à un dispositif de dosage, dans lequel le dispositif de dosage comprend une membrane recevant l'échantillon qui conduit l'écoulement d'un échantillon liquide en contact d'écoulement avec une membrane de détection d'analyte qui conduit l'écoulement de l'échantillon;

dans lequel la membrane de détection d'analyte comprend une membrane formant un conjugué et comprenant un premier et un deuxième réactif de marquage mobile à un situs de marquage et un premier et un deuxième réactif de capture à un situs de capture;

dans lequel le premier réactif de marquage est capable de former un complexe avec une HRP II, HRP III ou un fragment ou une variante de celles-ci; le deuxième réactif de marquage est capable de former un complexe avec une protéine de polyasparagine; le premier réactif de capture est capable de lier un complexe HRP II-, HRP III-réactif de marquage, et le deuxième réactif de capture est capable de lier un complexe protéine de polyasparagine-réactif de marquage, et

dans lequel l'échantillon liquide s'écoule d'une membrane recevant l'échantillon et se mélange avec le réactif de marquage mobile pour déplacer le réactif de marquage mobile en direction du situs de contrôle, et l'observation du résultat du dosage,

dans lequel les protéines de polyasparagine sont exprimées par une espèce de Plasmodium et comprennent 12 ou plus résidus successifs d'acide aminé asparagine.

20. Procédé selon la revendication 19, dans lequel l'échantillon est de l'urine.

21. Procédé selon la revendication 13 ou 19, dans lequel une accumulation de particules au situs de capture produit un signal indicative de la présence de l'analyte de Plasmodium dans l'échantillon.

Figure 1




Figure 2




Figure 3




Figure 4








Figure 5



*4a5 antibody recognizes
rHRP II but not rHRP III
when used as Primary Ab
for Indirect ELISA

3a4 antibody recognizes both
rHRP II and rHRP III when
used as Primary Ab
for Indirect ELISA

Figure 6





Figure 7



Lanes; 1 Pv (D19), 2 Pf (3d7), 3 *P. yoelii*, 4 *P. knowlesi*,
5. *P. brasilaneum*, 6. *P. Ovale*, 7. Pv (D73) 8. *P. chabaudi*

Figure 8

PfHRP II

MVSFSKNKVL SAAVFASVLLLDNNNSAFNNNLCSKNAKGLNLNKRL LHETQAH
 VDDAHHAHHVADAHHAHHAADAHHAHHAADAHHAHHAADAHHAHHAADA
 HHAHHAAYAHHAHHAADAHHAHHASDAHHAADAHHAAYAHHAHHAADAHH
 AHHASDAHHAADAHHAAYAHHAHHAADAHHAADAHHATDAHHAHHAADAR
 HATDAHHAADAHHATDAHHAADAHHAADAHHATDAHHAADAHHATDAHHA
 ADAHHAADAHHATDAHHAHHAADAHHAAAHHATDAHHAATDAHHAAAHHEA
 ATHCLRH

PfHRP III

MVSFSKNKIL SAAVFASVLLLDNNNSEFNNNLFSKNAKGLNSNKRL LHESQAHA
 GDAHHAHHVADAHHAHHAANAHHAANAHHAANAHHAANAHHAANAHHA
 NAHHAANAHHAANAHHAANAHHAANAHHAANAHHAANAHHAANAHHAAN
 AHHAANAHHAADANHGFFHNLHDNNSHTLHAKANACFDDSHHDDAHHDGA
 HHDDAHHDGAHHDDAHHDGAHHDDAHHDGAHHDDAHHDGAHHDDGAHHDG
 AHHNATTHHLHH

Figure 9

MONOCLONAL 3A4




Figure 10





Figure 11



Up close of frozen archival urine
test

Figure 12

The empty black box is
where a purple square of
reagents with antibodies was
impregnated.




Figure 13

parasites par/ul	Malaria Symptom	aldolase	HRP II	control
3000	No			
1760	No			
2400	No			
6200	No			
1200	No			
10000	Yes			
13000	Yes			
34000	Yes			
2800	Yes			
25600	Yes			
13700	Yes			
18470	Yes			

FIGURE 14




FIGURE 15




FIGURE 16




FIGURE 17.





FIGURE 18



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 2004053086 A [0003]
- FR 2791685 A [0004]
- WO 02092628 A [0005]
- US 2002127241 A [0006]
- US 4313734 A [0046] [0075]
- US 4366241 A [0046]
- US 4340482 A [0054]
- US 4618533 A [0054]
- US 5578577 A [0072]
- US 5141850 A [0072]
- US 4775636 A [0072]
- US 4853335 A [0072]
- US 4859612 A [0072]
- US 5079172 A [0072]
- US 5202267 A [0072]
- US 5514602 A [0072]
- US 5616467 A [0072]
- US 5681775 A [0072]
- US 5252496 A [0073]
- US 5559041 A [0073]
- US 5529901 A [0073]
- US 5294370 A [0073]
- US 5348891 A [0073]
- US 5641689 A, ATO [0073]
- US 5096837 A [0086]

Non-patent literature cited in the description

- **GARDNER, MJ et al.** Genome sequence of the human malaria parasite *Plasmodium falciparum*. *Nature*, 2002, vol. 419, 498-51 [0050]
- **KISSINGER, J.C.** The *Plasmodium* Genome Database. *Nature*, 2002, vol. 419, 490-492 [0050]
- **STAHL.** *NAR*, 1985, vol. 13, 7837 [0051]
- **IRVING ; CROSS.** *Mol. Biochem. Parasitol.*, 1986, vol. 18 (2), 223-234 [0051]
- *Nature*, 1984, vol. 312, 616 [0051]
- **WELLEMS.** *Proc. Natl. Acad. Sci. U.S.A.*, 1986, vol. 83 (16), 6065-6069 [0051]
- AF202093 HRP III FCC1/HN china. *Zhongguo Jishengchongbing Fangzhi Zazhi*, 2001, vol. 14 (2), 95-99 [0051]
- **SUGANO, S.** *Gene*, 1997, vol. 200 (1-2), 149-156 [0051]
- **G. FRENS.** *Nature Physical Science*, 1973, vol. 241, 20 [0072]
- **HORISBERGER.** Evaluation of Colloidal Gold as a Cytochromic Marker for Transmission and scanning Electron Microscopy. *Biol. Cellulaire*, 1979, vol. 36, 253-258 [0075]
- **LEUVERING et al.** *Sol Particle Immunoassay, J. Immunoassay*, 1980, vol. 1 (1), 77-91 [0075]
- **FRENS.** Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions. *Nature, Physical Science*, 1973, vol. 241, 20-22 [0075]
- Laboratory Techniques in Biochemistry and Molecular Biology. **TIJSSEN.** Practice and Theory of Enzyme immunoassays. vol. 15, 297-328 [0092]
- **ALTSCHUL S. et al.** Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. *Nucleic Acids Research*, 1997, vol. 25, 3389-3402 [0137]
- This volume contains a series of papers dedicated to description of the APL biological weapons detection effort. *APL Technical Digest*, 1999, vol. 20 (3 [0137]
- **BROWN, G. ; COPPEL, R. ; VRBOVA, H. ; GRUMMONT, R. ; ANDERS R. P.** *falciparum*: comparative analysis of erythrocyte stage-dependent protein antigens. *Exp. Parasitology*, 1982, vol. 53, 279-84 [0137]
- **COHEN, S. ; CHAIT, B.** Mass Spectrometry of Whole Proteins Eluted from SDS-PAGE Electrophoresis Gels. *Analytical Biochemistry*, 1997, vol. 247, 257-267 [0137]
- **CORNISH, T. ; BRYDEN, W.** Miniature Time-of-Flight Mass Spectrometer for a Field-Portable Biodetection system. *APL Tech. Digest*, 1999, vol. 20, 335-341 [0137]
- **COWMAN, A.** Functional analysis of drug resistance in *Plasmodium falciparum* in the post-genomic era. *Int. J. Parasitol.*, 2001, vol. 31, 871-8 [0137]
- Investigations of renal function. **DENNIS, V.** Cecil Textbook of Medicine. 1988, 492-499 [0137]
- **FENTON, B. ; WALKER, A. ; WALLIKER, D.** Protein variation in clones of *P. falciparum* detected by 2-D electrophoresis. *Mol. Biochem. Parasitology*, 1985, vol. 16, 173-83 [0137]
- **GARDNER, M. et al.** Chromosome 2 Sequence of the Human Malaria Parasite *P. falciparum*,. *Science*, 1998, vol. 282, 1126-1132 [0137]

- **GENTON, B. ; PAGET, S. ; BECK, H. ; GIBSON, N. ; ALPERS, M. ; HUI, J.** Diagnosis of Plasmodium Falciparum Infection Using Parasight-F Test in Blood and Urine of Papua New Guinean Children. *South-east Asian J. Tropical Medicine Public Health*, 1998, vol. 29, 35-40 [0137]
- **GOBOM, J. ; NORDHOFF, E. ; MIRGORODSKAYA, EKMAN, R. ; ROEPSTORFF, P.** Sample Purification and Preparation Technique Based on Nano-Scale Reverse-Phase Columns for the Sensitive Analysis of Complex Peptide Mixtures by MALDI-MS. *J. Mass Spectrometry*, 1999, vol. 34, 105-116 [0137]
- **GODOVAC-ZIMMERMANN, J. ; BROWN, L.** Perspectives for Mass Spectrometry and Functional Proteomics. *Mass Spectrometry Reviews*, 2001, vol. 20, 1-57 [0137]
- **HODDER, A. ; CREWETHER, P. ; MATTHEW, M. ; REID, G. ; MORITZ, R. et al.** The Disulfide Bond Structure of Plasmodium Apical Membrane Antigen-1. *J. Biological Chemistry*, 1996, vol. 271, 29446-29452 [0137]
- **HOWELL, S. ; WITHERS-MARTINEZ ; KOCKEN, C. ; THOMAS, A. ; BLACKMAN, M.** Proteolytic Processing and the Primary Structure of P. falciparum Apical Membrane Antigen-1. *J. of Biological Chemistry*, 2001, vol. 276, 31311-31320 [0137]
- **HURST, G. ; BUCHANAN, M. ; FOOTE, L. ; KENNEL, S.** Analysis for TNF- α Using Solid Phase Affinity Capture with Radiolabel and MALDI-MS detection. *Analytical Chemistry*, 1999, vol. 71, 4727-2733 [0137]
- **KAPPE, S. et al.** Exploring the Transcriptome of the Malaria Sporozoite Stage. *Proc. Natl. Academy Sci USA*, 2001, vol. 98, 9895-9900 [0137]
- **KARAS, M. ; BACHMANN, D. ; HILLENKAMP, F.** Influence of the Wavelength in High-Irradiance UV Laser Desorption Mass Spectrometry of Organic Molecules. *Analytical Chemistry*, 1985, vol. 57, 2935-2939 [0137]
- **KARAS, M. ; BACHMANN, D. ; BAHR, U. ; HILLENKAMP, F.** Matrix-Assisted Ultraviolet Laser Desorption of Non-volatile Compounds. *International Journal of Mass Spectrometry Ion Processes*, 1987, vol. 78, 53-68 [0137]
- **KARAS, M. ; HILLENKAMP, F.** Laser Desorption of Proteins with Molecular Masses Exceeding 10 kDa. *Analytical Chemistry*, 1988, vol. 60, 2299-2301 [0137]
- **KATZIN, A. ; KIMURA, E. ; ALEXANDRE, C. ; VAL RAMOS, A.** Detection of Antigens in Urine of Patients with Acute Falciparum and Vivax Malaria Infections. *Am. J. Trop. Med. Hyg.*, 1991, 453-462 [0137]
- **KEOUGH T. ; YOUNGQUIST, R. ; LACEY, M.** A method for high sensitivity peptide sequencing using postsource decay MALDI-MS. *Proc. Natl. Academy Sci. USA*, vol. 96, 7131-7136 [0137]
- **KUSSMANN, M. ; NORDHOFF, E. ; RAHBEK-NIELSEN, H. ; HAEBEL, S. ; ROSEL-LARSEN M. et al.** MALDI-MS Sample Preparation Techniques Designed for Various Peptide and Protein Analytes. *J. Mass Spectrometry*, 1997, vol. 32, 593-601 [0137]
- **MILITAO, D.N. ; CAMARGO, L.M. ; KATZIN, A.M.** Detection of Antigens in the Urine of Patients with Acute Plasmodium vivax Malaria. *Experimental Parasitology*, 1993, vol. 76, 115-120 [0137]
- **NELSON, R. ; JARVIK, J. ; TAILLON, B. ; TUBBS, K.** BIA/MS of Epitope-Tagged Peptides Directly from E. coli Lysate: Multiplex Detection and Protein Identification at Low-Femtomole to Subfemtomole Levels. *Analytical Chemistry*, 1999, vol. 71, 2858-2865 [0137]
- **NEUBAUER G. ; KING, A. ; RAPPSILBER, J. ; CALVIO, C. ; WATSON, M. ; AJUH, P. ; SLEEMAN, J. ; LAMOND, A. ; MANN, M.** Mass spectrometry and EST-database searching allows characterization of the multi-protein spliceosome complex. *Nature Genetics*, 1998, vol. 20, 46-50 [0137]
- **PACHEBAT, J. ; LING, I. ; GRAINGER, M. ; TRUCO, C et al.** The 22 kDa component of the protein complex on the surface of P. falciparum merozoites is derived from a larger precursor, merozoite surface protein 7. *Molecular & Biochemical Parasitology*, 2001, vol. 117, 83-89 [0137]
- **PANDEY, A. ; MANN, M.** Proteomics to study genes and genomes. *Nature*, 2000, vol. 405, 837-846 [0137]
- **PETER, J. ; UNVERZAGT, C. ; LENZ, H. ; HOESEL, W.** Purification of Prostate-Specific Antigen from Human Serum by Indirect Immunosorption and Elution with a Hapten. *Analytical Biochemistry*, 1999, vol. 273, 98-104 [0137]
- **PINSWASDI C. ; THAITHONG, S. ; BEALE, G. ; FENTON, B. ; WEBSTER, H. ; PAVANAND, K.** Polymorphism of proteins in malaria parasites following mefloquine treatment. *Mol. Biochem. Parasitol.*, 1987, vol. 23, 159-64 [0137]
- **QIAN, X. ; ZHOU, W. ; KHALEDI, M. ; TOMER, K.** Direct analysis of the products of sequential cleavages of peptides and proteins affinity bound to immobilized metal ion beads by MALDI-TOF-MS. *Analytical Biochemistry*, 1999, vol. 274, 174-180 [0137]
- **RABILLOUD, T. ; BLISNICK, T. ; HELLER, M. ; LUCHE S. ; AEBERSOLD, R. ; LUNARDI, J. ; BRAUN-BRETON, C.** Analysis of membrane proteins by two-dimensional electrophoresis: Comparison of the proteins extracted from normal or P. falciparum infected erythrocyte ghosts. *Electrophoresis*, 1999, vol. 20, 3603-3610 [0137]

- **RODRIGUEZ-DEL VALLE, M. ; QUAKYI, I.A. ; AM-UESI, J. ; QUAYE, J.T. ; NKURUMAH, F.K ; TAYLOR, D.** Detection of Antigens and Antibodies in the Urine of Humans with Plasmodium falciparum Malaria. *J. Clin. Microbiology*, 1991, vol. 29, 1236-1242 [0137]
- **SAGOE-MOSES ; C PEARSON ; R PERRY, J ; JAGGER, J.** Risks to Healthcare Workers in Developing Countries. *New Eng. J Med.*, 2001, vol. 345, 538-541 [0137]
- **SCHRIEMER, D. ; LI, L.** Combining Avidin-Biotin Chemistry with MALDI-MS. *Analytical Chem.*, 1996, vol. 68, 3382-3387 [0137]
- **SEESOD, N. ; LUNDERBERG, J. ; HEDRUM, A. ; ASLUND, L. ; HOLDER, A. ; THAITHONG, S. ; UHLEN, M.** Immunomagnetic purification to facilitate DNA diagnosis of P. falciparum,. *J. Clin. Microbiology*, 1993, vol. 31, 2715-9 [0137]
- **Carbohydrate Metabolism of Asexual Stages. SHERMAN, I.** Malaria. ASM, 1998, 575 [0137]
- **SHEVCHENKO, A. ; JENSEN, O. ; PODTELEJNIKOV et al.** Linking genome and proteome by mass spectrometry: Large scale identification of yeast proteins from two dimensional gels. *Proc. Natl. Academy Science USA*, 1996, vol. 93, 14440-14445 [0137]
- **SHEVCHENKO, A. ; WILM, M. ; VORM, O. ; MANN, M.** Mass Spectrometric Sequencing of Proteins from Silver-Stained Polyacrylamide Gels. *Analytical Chemistry*, 1996, vol. 68, 850-858 [0137]
- **SPENGLER, B.** Post-source Decay Analysis in MALDI-MS of Biomolecules. *J. Mass Spectrometry*, 1997, vol. 32, 1019-1036 [0137]
- **TAIT, A.** Analysis of protein variation in P. falciparum by 2D electrophoresis. *Mol. Biochem. Parasitology*, 1981, vol. 2, 205-218 [0137]
- **WILKINS, M.** Proteome Research: New Frontiers in Functional Genomics. Springer-Verlag, 1997 [0137]
- **Detection of malaria antigens in urine, using a solid-phase radioimmunoassay: preliminary study. Ethiop Med J.**, July 1984, vol. 22 (3), 119-27 [0137]
- **Detection of antigens in urine of patients with acute falciparum and vivax malaria infections. Am J Trop Med Hyg.**, vol. 45 (4), 453-62 [0137]
- **Detection of antigens in the urine of patients with acute Plasmodium vivax malaria. Exp Parasitol.**, 1993, vol. 76 (2), 115-20 [0137]
- **Diagnosis of Plasmodium falciparum infection using ParaSight(R)-F test in blood and urine of Papua New Guinean children. Southeast Asian J Trop Med Public Health**, March 1998, vol. 29 (1), 35-40 [0137]
- **Rapid Manual Diagnosis of Plasmodium falciparum Malaria Using ParaSight-F Dipsticks Applied to Human Blood and Urine. J Travel Med.**, 01 September 1996, vol. 3 (3), 172-173 [0137]
- **Detection of antigens and antibodies in the urine of humans with Plasmodium falciparum malaria. J Clin Microbiol.**, June 1991, vol. 29 (6), 1236-42 [0137]
- **describes P.falciparum from all over the world with a tree showing genetic distance between strains. Nature**, 2002, vol. 418, 323-6 [0137]

专利名称(译)	疟原虫诊断测定		
公开(公告)号	EP1853914B1	公开(公告)日	2015-04-22
申请号	EP2006719512	申请日	2006-01-25
[标]申请(专利权)人(译)	约翰霍普金斯大学		
申请(专利权)人(译)	约翰·霍普金斯大学		
当前申请(专利权)人(译)	约翰·霍普金斯大学		
[标]发明人	SULLIVAN DAVID J SCHOLL PETER		
发明人	SULLIVAN, DAVID, J. SCHOLL, PETER		
IPC分类号	G01N33/53 G01N33/573		
CPC分类号	G01N33/56905 G01N2333/445 Y02A50/58		
优先权	60/646893 2005-01-25 US		
其他公开文献	EP1853914A4 EP1853914A2		
外部链接	Espacenet		

摘要(译)

本发明涉及液体样品如体液中的疟原虫分析物的测定。更具体地，本发明涉及用于检测体液例如尿液或血液中的配体的方法和装置，其可以诊断疟疾感染。

MVSFSKNKVLAAVFAVLLDNNNSAFNNLCSKNAGLNLNKRLL
 HETQAHVDDAHHAHVADAHHAHAADAHHAHAADAHHAHAADAHH
 AHHAADAHHAHAAYAHHAHAADAHHAHASDAHHAADAHHAAYAHH
 AHHAADAHHAHASDAHHAADAHHAAYAHHAHAADAHHAADAHHATD
 AHHAHAADARHATDAHHAADAHHATDAHHAADAHHAADAHHATDAH
 AADAHHATDAHHAADAHHAADAHHATDAHHAHAADAHHAHAHATDA
 HHATDAHHAHAHHAATHCLRH (SEQ ID NO: 1)